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1. Introduction 
 
1.1 Definition and prevalence 
 
Fabry’s disease (FD) is a rare inherited X-linked lysosomal storage disease 
caused by deficient or absent activity of the enzyme α-galactosidase A 
(alpha-D-galactoside galactohydrolase (α-GAL); EC 3.2.1.22) due to mutations 
in the GLA-gene. The enzymatic defect leads to the systemic accumulation of 
glycosphingolipids, mainly globotrioacylceramide (GL-3) in a wide variety of 
tissues including vascular endothelium, renal glomeruli and tubules, dorsal root 
ganglia, cardiac myocytes, conducting tissue and valves, cornea, and skin 1.  
 
The German dermatologist, Johannes Fabry and the English dermatologist, 
William Anderson, independently described the first patients with FD in 1898 2,3, 
and therefore the disease is also known as “Mobus Anderson-Fabry”.   
 
FD is a X-linked rare hereditary disorder which affects more males than females: 
It is estimated that 1 in 40,000 4 males has FD, whereas the estimated 
prevalence in the general population is 1 in 117,000 people 5. In recent years, 
more researches have revealed that this disorder is probably underdiagnosed. 
In a screen of 37,104 newborns for α-galactosidase A, the incidence of FD was 
found to be 1:4600 6. In urinary screenings of patients who were undergoing 
hemodialysis to treat end-stage renal disease, 1.2% were shown to have FD 7.  
With patients who had cryptogenic stroke or hypertrophic cardiomyopathy, the 
prevelance was also relatively high 8-10.  
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1.3 Heredity and Mechanisms 
 
The GLA-gene is located on the X chromosome, which means a male patient 
will only pass his X chromosome on to his daughters. His daughters may not 
have FD but be only Fabry carriers, because the daughters’ other X 
chromosome will likely carry a healthy gene that is capable of making α-GAL. 
On the other hand, if a mother carries the Fabry gene, there is a 50% chance 
that she will pass the gene on to her sons or daughters. Her sons who inherit 
the gene will have FD. Her daughters who inherit the gene will be carriers, but 
may also be affected by FD, see below. 
 
The 12-kilobase long GLA-gene is located at Xq22 on the long arm of the X 
chromosome; it has seven exons 11, and encodes a 55-kDa precursor 
glycoprotein which is then proteolytically cleaved to the mature 51-kDa α-GAL 
12. α-GAL is a homodimeric glycoprotein consisting of 2 identical 49-kDa 
subunits; each monomer is composed of two domains (Fig 1.), and domain 1 
contains the active site. After binding a galactosylated substrate (primarily 
globotriaosylceramide), α-GAL cleaves the glycosidic linkage and removes the 
galactose from the glycolipids during the catabolism of macromolecules 13.  
 
Mutations in the GLA-gene leads to absent or deficient synthesis of α-GAL with 
two corresponding general phenotypes. The classic (or severe) phenotype 
shows no α-GAL activity detectable in the tissues and has symptoms affecting 
multiple organ systems, and the mild phenotype shows some residual α-GAL 
activity and has symptoms generally restricted to cardiac or renal anomalies14. 
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Fig. 1. Mechanism of the FD, modified from 11,12 
 
Due to the lack of α-GAL activity, deposition of GL-3 occurs in plasma and in 
the tissue lysosomes, increasing the risk for characteristic acroparesthesia of 
the hands and feet, angiokeratoma, strokes, hearing loss, myocardial 
microvascular ischemia and infarctions, arrhythmias, hypertrophic 
cardiomyopathy, valvular insufficiency, gastrointestinal symptoms, hypohidrosis, 
temperature and exercise intolerance, dysregulation of vascular tone and 
autonomic functions, obstructive lung disease, and chronic kidney disease 
leading to kidney failure. 
 
To date, more than 400 different mutations of GLA-gene have been reported 15, 
but the genotype/ phenotype correlations are only partially established since 
most patients have “private mutations” (i.e., confined to a single Fabry 
pedigree), with the exception of N215S, R227Q, R227X, R342Q, and R342X, 
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which were each found in several unrelated families from different ethnic 
backgrounds 16. N215S was a common mutation among atypical hemizygotes 
who were asymptomatic or had mild disease manifestations; while R227Q and 
R227X were the most common mutations causing the classical phenotype 17. 
Recently a direct correlation was reported between the levels of urinary 
excretion of GL-3/creatinine and the types of mutations; and patients with the 
A143P mutation suffered more severe symptoms 18. 
 
 
1.3 Clinical manifestations  
 
1.3.1 General clinical manifestations 
 
FD is a multisystem disorder with a wide range of symptoms which can affect 
both males and females. Virtually all males with the Fabry gene develop the 
disease and are likely to express some or many of the classic Fabry symptoms. 
In women however, symptoms can range from none (in asymptomatic carriers) 
to very serious manifestations similar to those seen in males.  
 
The Fabry Registry is a global ongoing, observational database that tracks 
natural history and outcomes of patients with FD. According to its latest survey 
based on 2236 patients (1159 male, 1077 female), male patients were generally 
more severely affected than female patients, and the symptoms developed 
about 5~10 years later with female than male patients 19. The age when first 
Fabry symptoms were recognized was 13.5 +/-12.1 years with male and 19.9 
+/-15.7 years with female patients, and their Fabry diagnosis was made with 
male at 26.3+/- 15.5 years and with female 32.1+/- 17.6 years. There was no 
significant difference of the time from symptom onset to diagnosis between 
male (14.2 +/-13.0 years) and female (15.7+/-14.8 years) patients. 
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Males with FD present early in life (4–8 years of age) with burning pain in their 
hands and feet, paresthesias (spontaneous or evoked abnormal sensations 
that are not unpleasant) and hypohidrosis 20,21. Angiokeratoma, a characteristic 
skin disorder of flat dark red to blue colored lesions, is found primarily in the 
bathing trunk area and the mucosal membranes from adolescence. Corneal 
and lenticular opacities appear around the same time. Fatigue, vertigo, and 
dizziness occur later in life. Life-threatening symptoms, including 
cerebrovascular events, cardiovascular symptoms and events (hypertrophic 
cardiomyopathy, valve disease, arrhythmias and myocardial infarction) and 
kidney disease, are among the latest occurring manifestations, and would 
cause death in the third to fifth decade in the absence of interventions such as 
hemodialysis, kidney transplantation, and heart protective measures 22.  
 
 
1.3.2 Women and children 
 
Formerly, females were considered only rarely to be as severely affected as 
males due to “X chromosome inactivation” 23,24. However, now it is 
acknowledged that female Fabry carriers can experience all symptoms of FD, 
although the onset of symptoms is not as early as is typically observed in males, 
and there is considerable variation between individuals. 
 
Cardiac involvement was the most common serious manifestation of FD among 
the females. LVH and major cardiac events occurred nearly 10 years later in life 
among females than in males. Cardiac involvement in children with Fabry is 
also frequent and may progress even at young age 25. Strokes occurred in 4.2% 
of the females at a median age of 43.5 years. This was about 5 years later in 
occurrence than in males. Gastrointestinal and renal symptoms are very 
common among males and females, although the age of onset is later among 
females. End-stage renal disease is less common in females with FD than in 
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males and develops at approximately the same age (median of 38 years) for 
both male and female patients.  
 
The most frequent early clinical manifestations of FD with children are also 
neurological (acroparesthesia, altered temperature sensitivity) symptoms. 
Recurrent abdominal cramps and diarrhea are the second most common 
presenting symptoms 26. Tinnitus, vertigo, fatigue and angiokeratoma were 
noted in early childhood and occurred with similar frequency in boys and girls, 
although the onset of symptoms was 2-5 years later in girls than in boys. There 
was an approximately 3-year delay from onset of symptoms to diagnosis with 
children 27. 
 
 
1.4 Diagnosis 
 
Typical signs like angiokerotomata of the skin of the trunk area and cornea 
verticillata are clues leading to the diagnosis. But since FD is rare, and the 
patients may have only a few of the typical symptoms, genetic diagnosis is 
essential. Because FD is an X-linked disorder and most cases result from 
inherited mutations rather than new mutations, identification of affected males 
is relatively easy, by using a combination of pedigree analysis and 
measurement of α-GAL activity in plasma or leukocytes. The identification of 
carrier females is more difficult because many have normal levels of α-GAL. 
The presence of the characteristic cornea verticillata or the demonstration of 
increased concentrations of GL-3 in urine sediment is highly suggestive of the 
diagnosis. However, the only way to make a definitive diagnosis is to show that 
the female carries the same GLA-gene mutation as her affected male relative. 
In symptomatic women who do not have an affected male relative with a 
GLA-gene mutation, identification of a disease-causing mutation is often difficult 
and time consuming 28. 
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1.5 Treatment 
 
1.5.1 Enzyme Replacement Therapy (ERT) 
 
The first case of FD was reported in 1898; and in 1970, α-GAL was identified. 
Over the hundred of years, the therapy was merely confined to symptomatic 
treatment (e.g., analgesics, dialysis, and renal transplantation); until 2001, the 
first medication for Enzyme Replacement Therapy (ERT) was approved in 
Europe. 
 
Two pharmaceutical companies have developed enzyme replacement therapy 
in FD: agalsidase alfa and agalsidase beta. Both are versions of human α-GAL 
that are produced in genetically engineered cell lines by different techniques. 
The recommended doses of agalsidase alfa and agalsidase beta are 0.2 mg/kg 
and 1.0 mg/kg biweekly, respectively. Only agalsidase beta is approved for 
treatment for FD in the United States, although both agents are approved for 
clinical use in other countries. Enzyme replacement therapy with either drug is 
very expensive, costing approximately $250 000 per year for the average adult 
with the disease. 
 
ERT has a primary role in the treatment of patients with FD. Numerous patients 
have now been treated using this approach, and randomized, 
placebo-controlled clinical trials and longer-term, open-label extension studies 
have shown that ERT could reduce the GL-3 levels in plasma and urine 
sediment; and accumulation of GL-3 in capillary endothelial cells, renal 
glomerular cells, and tubular epithelial cells as well 14,29.  
 
Relief of gastrointestinal symptoms is one of the earliest and most consistently 
beneficial effects of ERT 30. Positive effects on hypohidrosis, neuropathic pain, 
and small-fiber function were reported 31. Many reports have described 
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stabilization and even significant improvement of renal function and 
cardiomyopathy, and ERT may be able to slow down the natural decline in renal 
function in patients with moderate reduction in glomerular filtration rate. 
Although patients with normal or only mildly abnormal renal function seem to 
remain stable while receiving ERT, renal function deteriorates in those with 
glomerular filtration (GFR) rates less than 55 ml/min per 1.73 m2, although 
perhaps at a slower rate 32. Cerebrovascular attacks have occurred in some 
patients despite ERT, but the rate of progression was slowed 33. In conclusion, 
among patients with FD, a subpopulation with impaired renal function (reduced 
glomerular filtration rate, proteinuria, glomerulosclerosis) at baseline has a less 
favorable outcome and may develop renal progression despite treatment with 
ERT 34. Advanced baseline cardiac involvement (late enhancement) also 
appears to predict a less favorable cardiac course of disease 35.  
 
 
1.5.2 Other treatments 
 
Besides of ERT, other possible treatment options have also been developed, 
although they have not yet been implemented due to the requirement of further 
research to show whether they are feasible for use in patients.  
 
Enzyme enhancement (chaperone) therapy: In FD, premature degradation 
of α-GAL was demonstrated to occur within the endoplasmic 
reticulum-associated degradation as a result of the misfolding of mutant 
proteins. Strategies directed at preventing premature degradation by 
pharmacologic stabilizing of the mutant protein have been shown to 
substantially increase residual α-GAL activity 36. Because the level of enzyme 
activity necessary to prevent the disease is relatively low (<10%), even a 
modest increase in chaperone-induced enzyme activity might be expected to 
arrest the progression of FD. 1-Deoxygalactonojirimycin is one of the most 
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potent inhibitors of alpha-galactosidase A. It has also been shown to be the 
most effective active-site-specific chaperone at increasing residual enzyme 
activity in cultured fibroblasts and lymphoblasts established from Fabry patients 
with a variety of missense mutations. Such active-site-specific chaperone 
approach using functional small molecules may be broadly applicable to FD 
and other lysosomal storage disorders 37. 
 
Restriction of GL-3 synthesis (substrate reduction therapy) and gene therapy 
are other approaches that are being investigated 38,39.  
 
 
1.6 Small fiber involvement in FD and its reaction to ERT 
 
1.6.1 Neuropathic pain 
 
In FD, the accumulation of glycosphingolipids, mostly GL-3 in the central and 
peripheral nervous systems induces a predominantly small nerve fiber 
dysfunction.  
 
Two types of pain are described in patients with FD: the constant burning and 
lancinating neuropathic pain, and Fabry crises in which aggravated pain is 
observed in attacks induced by exercise, stress, and temperature changes, 
including fever. Fabry crises can last for a few minutes to several days, and are 
so debilitating that many patients are confined to bed. The pain is located 
largely in the hands and feet, but might also occur in joints, and is often 
associated with dysesthesias. 
 
Strong neuropathic pain affects about 65% male and 43% female patients 19,40. 
Acute pain crisis with acroparesthesia of prickling and burning character was 
typically the earliest symptom of FD, with a mean age at onset of 9.4 years in 
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boys and 16.9 years in girls 19,20. According to the International Association for 
the Study of Pain (IASP), acroparesthesia is defined as “numbness, tingling, or 
other abnormal sensations in one or more of the extremities”. In FD, the term is 
used for the burning pain and discomfort in the palms of the hands and the 
soles of the feet that occurs with fever and exercise. Although the term is a 
misnomer, it will be retained here, because it is so widely used in the 
FD-literature 1. Chronic pain syndromes become manifest later, at a mean age 
of 19.4±1.2 years. In FD, chronic neuropathic pain is thought to be in part 
caused by GL-3 deposition in dorsal root ganglia and sympathetic ganglia 41,42. 
Such deposits are likely to damage the neurons and nerve fibers and thus may 
lead to neuropathic pain in FD. In general, the level of pain appears to be stable 
during aging, although individual patients may have persistent pain, diminishing 
pain with age, or onset of pain later in life 19. Both acute pain attacks and 
chronic background pain have been reported as major causes of disability and 
psychiatric symptoms both in children and adults 43. 
 
ERT has been reported to significantly reduce pain and improve quality of life 
44,45. Patients who complained of severe pain at baseline showed the greatest 
improvement; and no patient who was pain free at baseline shifted to severe 
pain after 2 or 3 years of ERT 40. It is conceivable that clearance of nervous 
tissue from GL-3 may account for the improvements, but this hypothesis still 
needs confirmation by histological investigations. 
 
 
1.6.2 Small fiber neuropathy  
 
Neuropathic pain in Fabry patients may also be caused by the small fiber 
neuropathy. Sural nerve biopsies show a pronounced reduction of small 
diameter, thinly myelinated A-delta nerve fibers and unmyelinated C-nerve 
fibers. Large diameter, thickly myelinated fibers are less vulnerable and 
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therefore have rather well-preserved function. In accordance with the biopsy 
studies, quantitative sensory testing (QST) in Fabry patients showed significant 
Aβ-, Aδ-, and C-fiber dysfunction characterized by vibratory (VDT), cold (CDT), 
and heat-pain (HPT) detection threshold 46, while assessment of large, thickly 
myelinated fibers by means of nerve conduction studies (NCS) showed only 
mild impairment . Similarly, recordings of sympathetic skin responses (SSR) did 
not show significant changes in the Fabry patients, although hyperhidrosis is a 
frequent and early symptom 47.  
 
Early ERT steadily improves small nerve fiber function and sweat function 48, 
but such improvement can only be seen over 18 months consequent therapy, 
and ERT cannot improve nerve fiber function in patients with severe 
dysfunction of thermal perception such as loss of cold sensation 31. 
 
 
1.6.3 Intraepidermal nerve fiber density (IENFD) 
 
As the earliest symptom of FD, the neuropathic pain can occur in patients as 
young as 5 years of age. Although the pain may be severe, routine physical 
examination fails to detect any neurologic abnormality. Moreover, in patients 
who have not yet developed renal insufficiency, electrophysiologic studies and 
sural nerve biopsy detect no abnormality 46. Interest in studying cutaneous 
innervation has been kindled by the ability to visualize intraepidermal axons 
using antibodies to a panaxonal molecule, PGP 9.5. By counting the number of 
free nerve endings visualized in the epidermis, intraepidermal nerve fiber 
density (IENFD) can be determined 49. The most important value of skin biopsy 
is the ability to perform multiple biopsies over time. Serial biopsies could prove 
useful in detecting and quantitating increases in IENFD resulting from specific 
therapies such as ERT.  
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In recent years, significantly reduced IENFD in the distal leg was reported in FD 
patients 50,51,52, and patients demonstrated a greater proportional loss of 
innervation at the distal biopsy site than at the proximal biopsy site. Although 
patients with a small-fiber neuropathy showed significant improvement in 
thresholds for warm and cold temperatures in the hands and feet as well as a 
reduction in neuropathic pain by 3 years of ERT, no evidence of reinnervation 
was seen 53. While the IENFD in patients with stable normal kidney function 
was maintained over a period of 1 to 3 years 52, a continued decline of IENFD 
occurred in patients with severely impaired renal function 53.  
 
 
1.7 Aim of the study 
 
After the initiation of the enzyme replacement therapy (ERT) in Fabry patients, 
investigations concerning FD related peripheral neuropathy and its reaction to 
ERT suggest that ERT reduces neuropathic pain, improves sweating and 
peripheral nerve function in the hands and feet 31,48. However, distal epidermal 
nerve fiber regeneration could not be shown after 12-18 months of ERT 53. In 
addition, patients with impaired renal function at baseline have less favorable 
outcomes and may develop final stage events with kidney and heart despite 
treatment of ERT 35,54. Furthermore, ERT cannot improve nerve fiber function in 
patients with severe dysfunction of thermal perception such as loss of cold 
sensation 31. 
 
We therefore investigated the neurological function in patients with Fabry’s 
disease and its response to enzyme replacement therapy (ERT). Moreover, we 
looked into the role renal function plays on small fiber function in FD and its 
influence on ERT. We also tested whether ERT can induce proximal epidermal 
nerve fiber regeneration. 
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2. Methods 
 
2.1 Subjects 
 
To evaluate the neurological, especially small fiber involvement, in FD, we 
examined a cohort of 76 Fabry patients including 39 males (13.9-63 years) and 
37 females (8.9-68.8 years). The diagnosis was confirmed by family history, 
mutation and enzyme activity analysis. 37 patients (26 male, 11 female) were 
on ERT. The study was approved by the local ethics committee and all subjects 
had given written informed consent. All patients filled in the pain questionnaires 
NPSI and GCPS, and the depression questionnaire CES-D. All patients had 
neurological examination, quantitative sensory testing (QST), extra- and 
transcranial Doppler sonography and clinical neurophysiology including sural 
nerve conduction studies and the sympathetic skin response. 41 (22/39 male, 
19/37 female) patients agreed to have a skin biopsy, and 11 of them had 
repeated biopsy after one year follow up. 32 healthy volunteers served as 
control subjects for QST (mean age 43.5+/- 11.4 years, 40.6% men). They were 
age- and gender- matched to the patients groups.  
 
 
2.2 Pain and depression questionnaires  
 
Neuropathic Pain Symptom Inventory (NPSI) 55, a new self-questionnaire 
specifically designed to evaluate the different symptoms of neuropathic pain 
was used to help justify the neuropathic pain experienced by patients. NPSI 
includes 12 items: 10 descriptors reflecting spontaneous ongoing or 
paroxysmal pain, evoked pain (i.e. mechanical and thermal 
allodynia/hyperalgesia) and dysesthesia/paresthesia. The mean intensity of 
each of these items during the last 24 h had to be reported on a 0–10 numerical 
scale in which 0 was ‘no pain’ and 10 was ‘the most intense pain imaginable’. 
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Two additional categorical items evaluated the temporal sequence of 
spontaneous ongoing pain (i.e. number of hours during the last 24 h) and 
paroxysmal pain (i.e. number of paroxysms during the last 24 h). The German 
version of the NPSI is presented in Appendix A. 
 
The Graded Chronic Pain Scale (GCPS) 56 includes a measure of pain intensity 
and the extent to which pain is psychosocially disabling. The average of three 
pain intensity items is used to measure characteristic pain intensity. Disability 
days and ratings of interference with social, occupational, and recreational 
activities result in a disability score and a grade of severity of chronic pain 
status. Graded chronic pain categories correspond to the following: grade 0, 
pain free; grade I, low intensity pain and low interference; grade II, 
high-intensity pain, low interference; grade III, moderate interference; grade IV, 
high interference. Grades I and II correspond to a pain patient who is 
functioning adaptively to his pain, whereas grades III and IV correspond to 
dysfunctional adaptation. In this study, we used the total score of the three pain 
intensity items as an indicator of pain severity, and the total score of the three 
items rating interference with social, occupational, and recreational activities as 
disability score. The German version of the GCPS is presented in Appendix B. 
 
The CES-D (Center for Epidemiologic Studies Depression Scale) 57 is a short 
self-report scale designed to measure depressive symptomatology in the 
general population. This 20 item questionnaire includes six components: 
depressed mood; feelings of guilt and worthlessness; feelings of helplessness 
and hopelessness; psychomotor retardation; loss of appetite; and sleep 
disturbance. Respondents indicate how often within the last week they 
experienced the symptoms, responding: “rarely or none of the time” (0); “some 
or little of the time” (1); “occasionally or a moderate amount of time” (2); and 
“most or all of the time” (3). The scores for the 20 items are added, resulting in a 
range of possible total scores from 0 to 60. A total score higher than 16 is taken 
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as a indicator of depression. The German version of the CES-D is presented in 
Appendix C. 
 
 
2.3 Quantitative Sensory Testing (QST) 
 
2.3.1 Thermal detection, thermal pain thresholds and paradoxical heat 
sensations 
 
The tests for thermal sensation were performed using a Thermotest Type 1 
(Somedic AB, Sweden) thermal sensory testing device. Cold detection 
threshold (CDT) and warm detection threshold (WDT) were measured first. The 
number of paradoxical heat sensations (PHS) was determined during the 
thermal sensory limen procedure (TSL, the difference limen for alternating cold 
and warm stimuli), followed by cold pain threshold (CPT), and heat pain 
threshold (HPT). The mean threshold temperature of three consecutive 
measurements was calculated. All thresholds were obtained with ramped 
stimuli (1 °C/s) that were terminated when the subject pressed a button. Cut-off 
temperatures were 10 and 50 °C. The baseline temperature was 32 °C (center 
of neutral range) and the contact area of the thermode was 7.84 cm2. During 
the experiment, the subjects were not able to watch the computer screen. All 
thermal tests were first performed over cheek as a self control and then tested 
over dorsal foot.  
 
2.3.2 Mechanical detection threshold for modified von Frey filaments 
Mechanical detection threshold (MDT) was measured with a standardized set 
of modified von Frey hairs (Optihair2-Set, Marstock Nervtest, Germany) that 
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exert forces between 0.25 and 512 mN. The contact area of the von Frey hairs 
with the skin was of uniform size and shape (rounded tip, 0.5 mm in diameter) 
to avoid sharp edges that would facilitate nociceptor activation. The final 
threshold was the geometric mean of five series of ascending and descending 
stimulus intensities. 
 
2.3.3 Mechanical pain threshold for pinprick stimuli 
Mechanical pain threshold (MPT) was measured using a set of seven 
custom-made weighted pinprick stimulators (flat contact area of 0.2 mm 
diameter) that exert forces between 8 and 512 mN. Again using the “method of 
limits”, the final threshold was the geometric mean of five series of ascending 
and descending stimulus intensities. 
 
2.3.4 Stimulus–response-functions: mechanical pain sensitivity for 
pinprick stimuli and dynamic mechanical allodynia for stroking light 
touch 
Mechanical pain sensitivity (MPS) was tested using the same weighted pinprick 
stimuli as for MPT. To obtain a stimulus–response-function, these seven 
pinprick stimuli were applied in a balanced order, five times each, and the 
subject was asked to give a pain rating for each stimulus on a 0–100 numerical 
rating scale (‘0’ indicating “no pain”, and ‘100’ indicating “most intense pain 
imaginable”). 
Stimulus–response-functions for dynamic mechanical allodynia (DMA) were 
determined using a set of three light tactile stimulators: a cotton wisp exerting a 
force of ~3 mN, a cotton wool tip fixed to an elastic strip exerting a force of ~100 
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mN, and a standardized brush (Somedic, Sweden) exerting a force of 200~400 
mN. The three tactile stimuli were applied five times each with a single stroke of 
approximately 1–2 cm in length over the skin. They were intermingled with the 
pinprick stimuli in balanced order and subjects were asked to give a rating on 
the same scale as for pinprick stimuli. 
 
2.3.5 Wind-up ratio – the perceptual correlate of temporal pain summation 
for repetitive pinprick stimuli 
In this test of temporal summation, the perceived magnitude of a single pinprick 
stimulus was compared with that of a train of 10 pinprick stimuli of the same 
force repeated at a 1/s rate (128 mN, when tested over face, and 256 mN, 
when tested over hand and foot). The train of pinprick stimuli was given within a 
small area of 1 cm2 and the subject was asked to give a pain rating 
representing the pain at the end of the train using a numerical rating scale. In 
contrast to the more sophisticated technique of VAS-ratings at a 1/s rate this 
method is likely more appropriate for clinical routine assessment. Single 
pinprick stimuli were alternated with a train of 10 stimuli until both were done 
five times at five different skin sites within the same body region. The mean 
pain rating of trains divided by the mean pain rating to single stimuli was 
calculated as wind-up ratio (WUR). 
 
2.3.6 Vibration detection threshold 
Vibration detection threshold (VDT) test was performed with a Rydel–Seiffer 
tuning fork (64 Hz, 8/8 scale) that was placed over a bony prominence (cheek, 
processus styloideus ulnae, malleolus medialis). Vibration threshold was 
determined with three series of descending stimulus intensities.    
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2.3.7 Pressure pain threshold 
The final test in the protocol was performed with a pressure gauge device 
(FDN200, Wagner Instruments, USA) with a probe area of 1 cm2 (probe 
diameter of 1.1 cm) that exerts pressure up to 20 kg/cm2/~200 N/cm2/~2000 
kPa. The pressure pain threshold (PPT) is determined with three series of 
ascending stimulus intensities, each applied as a slowly increasing ramp of 50 
kPa/s. 
 
2.3.8 Statistics 
Two-sample t-tests were performed to analyze for differences between patients 
and controls for data with a normal distribution. In case of non-normality, 
Wilcoxon’s signed rank test was applied. All statistical calculations were 
performed by using the SPSS software 11.5 for Windows (SPSS Inc., USA). 
Log-data of thresholds were retransformed to linear values representing the 
original unit of each test.  
To compare the patients’ QST data profile with control data, the data were 
Z-transformed 58 for each single parameter by using the following expression: 
Z - score = (X single patient – Mean controls) / SD controls 
This procedure results in a QST profile where all parameters are presented as 
standard normal distributions (zero mean, unit variance). Z-values above “0” 
indicate a gain of function when the patient is more sensitive to the tested 
stimuli compared with controls, while Z-scores below “0” indicate a loss of 
function referring to a lower sensitivity of the patient. Thus, elevations of 
threshold (CDT, WDT, TSL, HPT, CPT, MDT, MPT, VDT, PPT) resulted in 
negative Z-scores, whereas increases in ratings (MPS, ALL, WUR) resulted in 
positive Z-scores. Paradoxical heat sensations (PHS) were interpreted as a 
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loss of thermodiscriminative function resulting in negative Z-scores.  
 
 
2.4 Neurological examination 
 
Detailed family history, pain complaints, analgesic treatment and possible pain 
triggers of the patients were recorded. Standard neurological examination was 
performed prior to skin biopsy. Renal status was based on medical records and 
creatinin-clearance.  
 
 
2.5 Clinical electrophysiological examination  
 
2.5.1 Sural nerve conduction studies 
 
72 patients underwent nerve conduction studies. With the patient reclined, the 
right foot was placed on a firm pillow. An antidromic sensory nerve conduction 
study was performed on the right sural nerve, using standard nerve technique. 
The sensory nerve action potential (SNAP) was recorded at the lateral 
malleolus with surface electrodes close to the nerve, amplified, digitized and 2 
recordings were averaged for off-line analysis (Duoliner, Toennies GmbH, 
Höchberg, Germany; filter settings: low cut 2 Hz, high cut 2 kHz). The SNAP 
was started by stimuli (1 ms in duration) at the midcalf, with surface electrodes 
(Toennies), using a distance from the recording electrode of more than 10 cm.  
Supramaximal stimulation was achieved by increasing the stimulation current 
until the amplitude of the SNAP did not further increase. For measurements of 
minimal SNAP latency and amplitude, 2 responses were averaged and the 
distance between the stimulating and recording electrode was measured. 
 
Measurements of sensory nerve conduction velocity and of SNAP amplitude 
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were compared to normal values of the laboratory. In all measurements, the 
temperature of the skin at both recording and stimulation sites was controlled 
using a thermometer, securing a temperature above 34°C. In case of low skin 
temperatures, the leg was warmed in a footbath.  
 
 
2.5.2 Sympathetic skin response 
 
SSR was recorded from the foot. The recording surface electrode was placed 
on the sole of the foot, while the reference electrode was placed on the dorsal 
side. The stimulus was electrical stimulation of the ipsilateral median nerve with 
the patient unaware of the stimulation time point. The tests were done using 
standard techniques with a Toennies Duoliner and analyzed with Toennies 
Duoliner software vers. 2.0 (Toennies). If no responses were recorded from two 
or more tests, the test result was considered abnormal. 
 
 
2.6 Extra- and transcranial Doppler sonography 
 
The subjects were studied in a supine resting state with their eyes closed. TCD 
examination was carried out by an experienced sonographer with ultrasound 
equipment (Model: PIONEER 2021, Inc.: NICOLET). The temporal window was 
used for studying middle cerebral artery (MCA), anterior cerebral artery (ACA) 
and posterior cerebral arteries (PCA) with a 2-MHz pulse-wave probe. The 
CCA, extra-cranial segment of internal carotid artery (ICA), vertebral artery (VA) 
and subclavian artery were insonated bilaterally by 4-MHz continuous wave 
Doppler probe.  
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2.7 Skin biopsy 
 
Intraepidermal nerve fiber density (IENFD) was assessed on five-mm punch 
biopsies (Disposable biopsy punch, WPI, USA) taken under sterile conditions, 
after topical anesthesia with 10 % lidocaine 49. Specimens were taken on the 
distal leg 10 cm proximal to the medial malleolus and on the back at Th12 level 
and 10 cm lateral to the spinal cord. These locations were chosen because it 
was clinically acceptable; the lengths of the axons at the distal leg are similar to 
those innervating the foot where quantitative sensory testing was done, and the 
IENFD at Th12 level on the back is much higher than that of distal leg and 
therefore can serve as good control. For the repeated biopsy, the site was 1 cm 
distal from the scar where last biopsy performed; when the scar was not 
obvious, the biopsy site was empirically determined by the operator.  
  
Specimens were fixed in fresh 4% buffered paraformaldehyde for 2 to 4 hours, 
washed in phosphate buffer and subsequently stored in 10% sucrose with 0,1M 
phosphate buffer until analysis. Fifty-μm cryostat sections were immunoreacted 
with the pan-neuronal marker PGP9.5 (1:800, Ultraclone, UK) and visualized 
with Cy3-labelled anti-rabbit antibodies (1:100, Amersham, USA). 
 
IENFD quantitation: Three immunofluorescence-stained biopsy sections per 
site were viewed with a Zeiss Axiophot 2 microscope (Wetzlar, Germany). 
Single unmyelinated sensory nerves were counted only if they crossed the 
basement membrane of the epidermis as previously described 59. Fibers that 
branched within the epidermis after crossing the basement membrane were 
counted as a single unit. Nerves that branched in or below the basement 
membrane and then traveled separately into the epidermis were counted as 
multiple units depending upon the number of branch points. Fragments in the 
epidermis that did not cross the basement membrane were not counted. The 
lengths of epidermis were digitized using a Image Pro Plus 4.0 software (Media 
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Cybernetics, Leiden, The Netherlands). The total number of fibers was divided 
by the total length of the counted sections and expressed as intraepidermal 
nerve fiber number per mm (IENFD, f/mm). Each section analyzed was counted 
by an observer blinded to the source of the specimens.  
 
The density of the subepidermal plexes was judged visually as “normal”, 
“slightly decreased”, “decreased”, or “depleted”. Our lab’s standard for distal 
IENFD (female: 9.5 +/- 3.7 f/mm, male: 10.4 +/ 2.5 f/mm) from 68 healthy 
volunteers (mean age 49.4 +/- 15.3; 42.6% men) was used as normal value for 
skin biopsies. We have not collected enough objects to draw a standard for 
proximal IENFD, and the corresponding comparison in this study was only 
performed within the patients.  
 
Statistics 
 
Two-sample t-tests were performed to analyze for differences between patients 
and controls for data with a normal distribution. In case of non-normality, 
Wilcoxons signed rank test were applied. Pearson and Spearman correlation 
coefficients were used to evaluate the relationship between clinical, QST, 
neurophysiologic and neuropathologic variables.  
P < 0.05 was considered significant. 
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3. Results           
 
3.1 Patients demographics and clinical characteristics 
 
As of May 6, 2008, a total of 76 patients were enrolled in the neurological 
screening of the Fabry Centre of Würzburg; 39 (51.3%) male and 37 (48.7%) 
female. Most patients had a positive family history of FD. 51 patients (67.1%) 
were detected via family screen, 9 patients (11.8%) through renal problems, 5 
patients (6.6%) through ophtalmological examination, 4 patients (5.3%) through 
cardiac examination, 3 (3.9%) through cerebral events, 2 (2.6%) through 
angiokeratoma, and two patients (2.6%) (mother and son) noticed their 
symptoms through the media and then turned to our center. All the patients 
were screened and followed up after one year. 21 patients were followed up for 
two years. We took patients younger than eighteen years as a subgroup and 
divided the adult patients into two subgroups based on their age (<40 and 
≥40years). Demographic and clinical characteristics are indicated in Table 1. 
 
Generally, male patients experienced higher frequencies of symptoms with 
kidney, heart and CNS than females. These differences were not large in 
patients older than 40 years, but in this group there were ten percent fewer 
female patients receiving ERT. The median age at diagnosis in females (38.1 
+/-16.4 years) was older than that in males (36.6+/-13 years), although with no 
significant difference.  
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Table1. Demographics and clinical characteristics in all Fabry patients 
 
Parameter Number of male patients Number of female patients 
Total number of patients n 39 37
current age (years) 
Median 
(range) 
39.3 (13.9, 63) 39.8 (8.9, 68.8)
Family members diagnosed with 
FD 
n (%) 37 (94.8%) 34 (91.9%)
Age category (years) 
0–<18 
≥18–<40 
≥40 
 
n (%) 
n (%) 
n (%) 
3 (7.7%)
15 (38.5%)
21 (53.8%)
5 (13.5%)
10 (27%)
22 (59.5%)
Age at FD diagnosis (years) 
Mean 
(SD) 
36.6 (13.0) 38.1(16.4)
Patients with renal problems 
Age category (years) 
0–<18 
≥18–<40 
≥40 
n (%) 
 
n (%) 
n (%) 
n (%) 
22 (56.4%)
0
5 (12.8%)
17 (43.6%)
12 (33.3%)
0
1 (2.7%)
11 (30.6%)
Patients with cardiac problems 
Age category (years) 
0–<18 
≥18–<40 
≥40 
n (%) 
 
 
n (%) 
n (%) 
n (%) 
23 (59.0%)
0
6 (15.4%)
17 (43.6%)
17 (47.2%)
0
3 (8.3%)
14 (38.9%)
Patients with CNS problems 
Age category (years) 
0–<18 
≥18–<40 
≥40 
n (%) 
 
n (%) 
n (%) 
n (%) 
10 (25.6%)
0
4 (10.3%)
6 (15.4%)
4 (11.1%)
0
1 (2.7%)
3 (8.3%)
Patients with hypohidrosis 
Age category (years) 
0–<18 
≥18–<40 
≥40 
n (%) 
 
n (%) 
n (%) 
n (%) 
17 (43.6%)
0
6 (15.4%)
11 (28.2%)
5 (13.5%)
0
2 (5.4%)
3 (8.1%)
Patients with auditory 
impairment 
Age category (years) 
0–<18 
≥18–<40 
≥40 
n (%) 
 
 
n (%) 
n (%) 
n (%) 
14 (35.9%)
0
3 (7.7%)
11 (28.2%)
7 (18.9%)
0
0
7 (18.9%)
Patients with α-GAL activity < 
0.4 nmol/min/mg protein 
n (%) 34 (100%) 24 (77.4%)
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Patients on ERT 
Age category (years) 
0–<18 
≥18–<40 
≥40 
n (%) 
 
n (%) 
n (%) 
n (%) 
26 (66.7%)
0
8 (20.5%)
18 (46.2%)
11 (30.6%)
0
1 (2.7%)
10 (27.0%)
 
 
3.2 General Neurological Symptoms and Findings 
 
The symptom most frequently reported in our cohort was pain, which affected 
30 of 39 male and 24 of 37 female patients (Fig. 2). 15 patients (13 m, 2 f) had 
constant burning pain in the limbs with GCPS pain score of 12+/-4, and 10 
patients (6 m, 4 f) also complained of numbness or tingling in this region. Nine 
patients (5 m, 4 f) reported fatigue. Hypohidrosis and auditory impairment were 
more prevalent in the male than in female group. Patients older than forty years 
had a higher incidence of hearing loss and tinnitus in both male and female 
groups. 14 patients had a history of cerebral events, but only two suffered from 
neurological sequelae. 15 patients (13 m, 2 f) had constant burning pain in the 
limbs, and 10 patients (6 m, 4 female) also complained of numbness or tingling 
in this region.  
 
On neurological and electrophysiological examination, 47 patients were normal. 
In 29 patients, minor abnormalities were found. These were: decreased tendon 
reflexes (n=12), minor sensory deficits (n=10); reduced amplitude of the 
sensory nerve action potential (SNAP) (n=13), and reduced or absent 
sympathetic skin response (SSR) (n=10). Extra- and transcranial Doppler 
sonography gave normal results in all patients.    
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Fig. 2. Neurological symptoms in Fabry patients. 
Neuro pain= neuropathic pain, Hypohidro= hypohidrosis, Cerebro= cerebral events, Audio 
imp= auditory impairment 
 
 
3.3 Pain and Depressive Symptoms 
 
Pain was reported by 30 of 39 male and 24 of 37 female patients. Together with 
the confirmation of the NPSI questionnaire (NPSI score ≥ 1/10) and patients’ 
description of ‘acroparesthesia’, neuropathic pain was reported in 34.2% of 
male and 21.1 % female patients (Fig. 2).  
 
Graded Chronic Pain Scale (GCPS) questionnaire and depression screening 
questionnaire (CES-D) data were available on 36 male and 35 female patients. 
The severity of pain (items 1-3 of GCPS) and pain related disability (items 4-6 
of GCPS) and depression were analyzed by comparing the mean scores of 
males and females with three age categories, as shown in Table 2.  
 
A CES-D score higher than 16 is thought to be an indicator of depression. In 
eight children we screened, five complained of pain, though with low severity 
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and little effect on daily life. None of the children showed an indication of 
depression. In adult patients, females younger than 40 years showed less pain 
related daily disability than patients older than 40 years (p= 0.046). There was 
no such difference between age groups in male patients. When comparing 
female with male patients, females younger than 40 years showed less pain 
related disability (p= 0.031) and also less depression (p= 0.034) than males 
younger than 40 years. Females older than 40 years suffered pain, pain related 
disability and depression as severely as male patients. 
 
Table 2. Severity of pain, pain related disability and depression 
 
  Male patients Female patients 
Age category 
(years) 
 
Pain 
score 
Disability 
score 
CES-D 
score 
Pain 
score 
Disability 
score 
CES-D 
score 
Pt. n (%) 2 (2.9%) 3 (4.3%)  
0–<18 Mean  1.0 1.0 10.0 3.3 1.0 10.3 
Pt. n (%) 14 (20%) 10 (14.3%)  
 
≥18–<40 
Mean 
(SD) 
9.2  
(6.6) 
8.2  
(6.9) 
18.8  
(6.3) 
5.1  
(5.6) 
2.1  
(3.4) 
10.3  
(5.9) 
Pt. n (%) 22 (31.4%) 22 (31.4%) 
 
≥40 
Mean 
(SD) 
7.7  
(5.6) 
6.4  
(6.2) 
15.9 
(10.4) 
7.1  
(7.7) 
7.7  
(9.6) 
17.3  
(14.0) 
Pt.= patient 
 
3.4 Quantitative sensory testing  
 
All 68 adult patients had QST and abnormalities were found in 63 (34/36male, 
29/32 female) of them (Fig.3). Male patients had more frequent abnormal QST 
profiles and significantly increased CDT (p<0.001), WDT (p<0.001) and TSL 
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(p<0.001) than female patients, which revealed that male patients had more 
severe thermal sensory loss than female patients.  
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Fig. 3. QST abnormalities in adult patients. 
 
 
3.4.1 Male patients 
 
A Z-score was calculated to describe the QST profile of the patients. As shown 
in Fig. 4a and Fig. 4b, compared with age and gender matched healthy controls, 
cold detection threshold (CDT) was significantly decreased in both patients 
older (n=22, p<0.001) and younger than 40 years (n=14, p<0.001). The older 
patients had also increased paradoxical heat sensations (PHS), which indicates 
the loss of sensory function. In patients younger than 40 years, wind-up ratio 
(WUR) was increased as a sign for sensitized Aδ- fibers, while the thermal 
sensory limen (TSL) and vibration detection threshold (VDT) were decreased, 
which are signs indicating the loss of sensory function of C- and Aβ- fibers 
respectively. Compared to patients with relatively normal renal function (n=26), 
patients with pathological renal function (n=10) had more decreased PHS and 
VDT, although without significant difference (Fig. 4c).   
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Fig. 4a. Z-score of male patients older than 40 years.  
 
Male patients, < 40y
-3
-2
-1
0
1
2
3
CDT  WDT TSL  PHS  CPT  HPT  MDT MPT  MPS  DMA  WUR VDT  PPT  
z-
sc
or
e
patients
controls
*
*
*
*
 
Fig. 4b. Z-score of male patients younger than 40 years.  
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Fig. 4c. Z-score of male patients with normal and pathological GFR. 
 
 
3.4.2 Female patients 
 
In 32 adult female patients, 29 had abnormal QST values, among them four had 
reduced CDT, nine had increased TSL, and 11 had abnormal PHS. However, as 
whole groups, no significant difference between patients and healthy controls 
was found in any item observed except for DMA in patients older than 40 years 
(Fig. 5a and 5b). Patients with pathological renal function (n=5) had increased 
dynamic mechanical allodynia (DMA) indicating a peripheral and central 
sensitization, and decreased thermal detection threshold compared to patients 
with normal renal function, although not statistically significant (Fig. 5c).  
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Fig. 5a. Z-score of female patients older than 40 years. 
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Fig. 5b. Z-score of female patients younger than 40 years. 
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Fig. 5c. Z-score of female patients with normal and pathological GFR.  
 
 
3.5 Skin innervation (IENFD) 
 
Skin biopsies from the dermatome Th12 and from the lower leg about 10 cm 
above the lateral malleolus were analyzed in 41 (22/39 male, 19/37 female) 
patients in whom these biopsies were taken for diagnostic reasons. Skin 
samples were processed for immunohistochemistry and the intra- and 
subepidermal innervation was quantified (Fig. 6). Compared to our laboratory’s 
normal values for Th12 and the lower leg, the intraepidermal innervation 
density was significantly reduced in male patients (18.0 +/- 8.8 fibers/mm 
proximally and 2.2+/-2.8 fibers/mm distally, Fig. 7a and 7b), and in most 
patients the density of the subepidermal nerve plexus was also reduced. In the 
19 female patients, we found less reduced mean intraepidermal innervation 
density (26.2 +/- 9.9 fibers/mm proximally and 6.3 +/- 4.3 fibers/mm distally), six 
had a reduced subepidermal plexus density.  
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a b c
Fig. 6. (a) Skin punch biopsy in a patient with FD. (b, c) Immunofluorescent stain of nerve 
fibers in the epidermis and subepidermis of a healthy control (b) and a Fabry patient (c). 
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Fig.7a. Distal IENFD in male and female patients. 
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Fig.7b. Proximal IENFD in male and female patients 
 
 
3.6 Follow up study 
 
Renal function has been reported to play an important role in the ERT effect on 
vital organs like kidney and heart 34,60. To look into its role in small fiber function, 
21 patients (17 male and 4 female) were divided into subgroups according to 
their renal function for the follow up study. 17 male and two of female patients 
were on ERT, two female patients with mild symptoms were taken as controls. 
Seven patients were screened for the third time and the other fifteen patients for 
the second time. All the follow up patients had electrophysiological 
examinations and completed the questionnaires on severity of pain (items 1-3 
of GCPS), pain related disability (items 4-6 of GCPS) and depression 
symptoms (CES-D). Data are displayed in Table 3. 
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Table 3. Neurological complaints and findings in the follow-up patients 
 
Sural nerve 
NCS  
Pt V Age  Time 
of 
ERT 
(year)
GFR 
(ml/m
in/1.7
3 m2) 
Neuropathic 
pain 
complaints 
Pain 
score
Disability 
score 
CES-D 
score 
Hypo
hidro
sis SNAP 
(µV) 
NCV 
(m/s) 
Male patients with GFR < 60 
FA V1 52.8 0.1 15 Y 12 16 25 Y 38 2.97 
 V2 53.9 1.1 14 Y 14 9 32 Y 36 1.5 
 V3 54.9 2.1 15 Y 9 5 10 Y 41 3.81 
KJ V1 40.4 3.2 10 Y 12 6 3 Y 40 9.6 
 V2 41.2 4.0 93 Y 12 6 5 N 46 6.2 
 V3 42.2 5.0 78 Y 11 6 4 N 49 13.7 
RW V1 48.2 5.0 23 Y 10 7 19 Y b  19.6 
 V2 49.2 6.0 5 Y 13 11 31  43 18.8 
FO V1 41.1 2.9 15 Y 10 13 2 Y 41 4.2 
 V2 42.2 4.1 13 Y 9 6 2 Y 40 2.75 
KR V1 40.8 5.3 11 N 13 5 10 N 37 5.2 
 V2 41.8 6.3   N 6 1 16 N 37 5.6 
BD V1 28.8 0 84 Y 14 0 19 Y 46 13.3 
 V2 29.7 1.1 58 Y 14 16 30 Y b 43 14.9 
 V3 30.7 2.0 58 Y 16 21 24 Y b 44 12.8 
Male patients with GFR ≥ 60 
RA V1 48.4 0.1 88 Y 0 0 11 Y 43 5.8 
 V2 49.4 1.1 68 N 0 0 9 Y 47 9.08 
LM V1 45.1 2.2 130 Y 0 10 26 Y 45 19 
 V2 46.1 3.0 111 Y 0 0 6 Y 44 18.2 
 V3 47.1 4.0 96 N 0 0 23 Y 43 18.3 
LS V1 41.1 3.2 95 Y 11 7 20 N 44 18.3 
 V2 42.1 4.2 90 Y 8 11 30 N 42 17 
 V3 43.2 5.3 98 Y 6 2 31  45 23.6 
LK V1 45.3 0.1 112 Y 9 3 11 N 46 23 
 V2 46.3 1.1 103 Y 12 6 17 N 46 16.4 
 V3 47.3 2.1 111  12 6 16 N 44 16.5 
KR V1 41.3 3.5 100 Y 14 13 17 N 41 16.5 
 V2 42.1 4.3 131 Y 17 15 35 N 44 11 
RA V1 40.4 3.0 106 Y 16 27 10 N 50 18.4 
 V2 41.4 4.0 195 Y b 9 5 23 N 47 17.8 
GS V1 37.3 0.2 102 Y 4 2 21 N 41 28.9 
 V2 38.2 1.2 102 Y b 7 3 20 N 45 32 
SW V1 38.8 4.1 119 Y 17 16 18 N   
 V2 39.8 5.1 72 Y b 16 10 18 N 40 5.6 
 V3 40.9 6.1 71 Y w 22 16 25 N 42 2.3 
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OT V1 22.2 0.1 150 Y 6 3 16 N 47 30.3 
 V2 23.3 1.2 107 Y b 10 9 16 Y b 49 30.5 
KD V1 19.2 0.0 132 Y 12 15 18 Y 50 30.9 
 V2 20.2 1.1 131 Y 11 16 22 Y     
RG V1 36.4 2.1 71 Y 5 3 20 Y 43 11.9 
 V2 37.2 3.0 75 Y b 7 4 22 Y 43 13 
Female patients with GFR < 60 
GR V1 44.8 0.1 50 N 13 6 34 N 43 6.5 
 V2 45.8 1.1 44 Y 21 23 25 N 52 11.7 
 V3 46.8 2.1 56 N 24 24 35 N 56 35.4 
TL V1 38.2 0 43 N 4 0 7 N 57 19.4 
 V2 39.2 1.0 48 N 4 0 10 N 54 26.5 
Female patients with GFR ≥ 60 (control) 
SS V1 41.7  98 Y 0 0 4 N 40 21.1 
 V2 43.7  125 Y 0 0 3 N 49 15.8 
PP V1 33.8  102 N 0 0 9 Y 45 25 
V2 34.9  135 N 0 0 6 N 46 33.1 
Pt: patient; V: visit; V1: 1st visit; V2: 2nd visit after one year; V3: 3rd visit after two years;  
Red: deteriorated; Green: improved; Y: yes; N: no; b: better; w: worse 
 
 
3.6.1 Neurological Symptoms and Findings 
 
As shown in the Table 3, in 19 follow up patients on ERT, seven patients with 
relatively normal renal function reported less severe acroparesthesia. Four 
patients reported better perspiration, including two patients with impaired renal 
function. One patient described that the improvement of pain and perspiration 
in the third year was not as obvious as during the first two years of the ERT 
initiation. Eight patients showed improved sural nerve NCS, while other thirteen 
patients had relatively stable values. No patient had a CNS event or worsening 
of cerebral blood flow parameters during the follow up observation.  
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3.6.2 Pain and Depressive Symptoms 
 
As shown in Table 3, in 19 follow up patients on ERT, seven patients with 
relatively normal renal function reported less severe acroparesthesia, three 
patients with pathological renal function also showed improved pain and pain 
related disability scores; eight patients had stable pain severity, only one patient 
complained of more pain. However the pain scores increased in 11 patients and 
the pain related disability scores also increased in 11 patients. The CES-D 
scores also increased in 15 patients, indicating more severe depression. Even 
in three patients whose pain and pain related disability scores obviously 
decreased, CES-D still increased.  
 
 
3.6.3 QST 
 
All 21 follow up patients had repeated QST, and the Z-score was used to 
describe their response to ERT.   
 
3.6.3.1 One year follow up  
 
Of 19 patients (17male, 2 female) who were on ERT, an improved CDT was 
found in four patients, improved WDT and CPT was found in four and one 
patient respectively. Impressive improvement was found in one patient (Fig. 8) 
with normal renal function. As shown in Fig. 9a and 9b, 12 of 18 male patients 
with relatively normal renal function showed a generally stable QST profile, 
while the 6 patients with severely impaired renal function had a deteriorated 
profile despite of ERT (Fig. 9c). Similar results were also found in the four 
female patients, among whom two with pathological renal function were on ERT 
(data not shown). 
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Fig. 8. Improved QST profile in a male patient with normal renal function.  
V1: First QST   V2: Second QST after one year  
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Fig. 9a. QST profile of follow up male patients older than 40y on ERT.  
V1: First QST   V2: Second QST after one year  
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Fig. 9b. QST profile of follow up male patients younger than 40y on ERT.  
V1: First QST   V2: Second QST after one year  
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Fig. 9c. Renal function and QST profile of follow up male patients on ERT.  
V1: First QST   V2: Second QST after one year  
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3.6.3.2 Follow up after two years 
 
Seven male patients have had the third time QST (Table. 4), and three of them 
had improved TSL, one had improved CPT and DMA. Interestingly, two of these 
three patients had pathological renal function. As shown in Fig. 10, although 
these patients were on ERT, their QST profile still showed slightly deteriorated 
thermal sensory function. 
 
Table 4. 2-year follow up QST values in seven patients on ERT. 
 
Pt V Age GFR CDT WDT TSL PHS CPT HPT MDT MPT MPS DMA WUR VDT PPT
FA V1 52 15 -5.57 3.43 5.9 3 10 45.57 0.35 17.15 7.48 0.19 2.63 5.67 530 
 V2 53 14 -22 17.1 40 0 10 50 10.56 34.3 24.26 0 1 4.67 540 
 V3 54 15 -22 16.07 27.03 0 10 50 2.14 6.5 1.86 0.59 2.31 5.33 389 
KJ V1 40 10 -15.17 4.23 16.43 1 10 43.57 3.25 45.25 6.67 0.83 2.15 5.5 500 
 V2 41 93 -22 3.8 33.13 0 10 47.33 0.87 90.51 2.59 0 1.93 6.33 379 
 V3 42 78 -5.07 7.37 18.57 0 19.73 47.17 1.41 90.51 2.34 0 1.80 5.00 419 
LM V1 45 130 -22 6.13 35.1 0 10 45.37 0.87 181.02 0.16 0 1.18 5.83 883 
 V2 46 111 -22 18 40 0 10 50 13 21.11 0.36 0 1.14 6.83 543 
 V3 47 96 -22 17.27 40 0 10 50 9.19 97.01 1.27 0 1.91 6.17 729 
LS V1 41 95 -10.63 11.53 19.47 2 11.5 44 0.54 274.37 0.41 0 2.67 6.33 510 
 V2 42 90 -20.33 17.63 40 3 10 50 0.81 137.19 0.44 0 2.17 7 386 
 V3 43 98 -21.07 16.33 34.4 2 10 48.8 0.71 238.86 0.52 0 2.1 6.33 487 
LK V1 44 112 -18.73 12 12.23 2 10 43.17 1.87 8 8.59 0 3.38 6 481 
 V2 45 103 -22 18 40 0 12.7 50 6.96 97.01 16.62 0 1.42 7.5 576 
 V3 46 111 -22 17 40 0 10 50 1.87 111.43 8.11 0 2.45 6.83 647 
GD V1 29 84 -19.43 2.6 22.9 0 10 44.47 1.07 48.5 7.43 0 1.56 6 428 
 V2 30 58 -22 3.87 27.93 0 10 38.43 1.74 90.51 2.82 0 2.26 5.83 549 
 V3 31 58 -22 4.43 29.27 0 10 42.17 2.14 84.45 1.78 0 6.67 5.67 399 
SW V1 39 119 -20.37 1.93 28.07 0 14.87 46.2 1.52 14.93 9.6 0.03 2.5 5.83 458 
 V2 40 72 -22 18 40 0 10.23 49.2 3.25 5.66 2.74 0 1 5.83 419 
 V3 41 71 -19.67 16.53 30.53 0 12.43 50 2.83 24.25 4.66 0 1.39 4.5 474 
Pt: patient; V: visit; V1: 1st visit; V2: 2nd visit after one year; V3: 3rd visit after two years; 
Red: deteriorated; Green: improved 
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Fig. 10. QST profile in 7 two-year follow up patients. V1: First QST   V2: Second QST 
after one year   V3: Third QST after two years 
 
 
3.6.4 Skin innervation (IENFD) 
 
Of 19 follow up patients under ERT, 11 had repeated skin biopsies, Table 5.  
 
Proximal IENFD: Four patients had increased IENFD from 11.3 +/- 2.3 f/mm to 21.1 
+/- 1.9 f/mm, and also improved peripheral neurological profiles; all of them had 
relatively normal renal function, including one patient with twice renal transplantation. 
Four patients had reduced IENFD, and all of them had severe renal impairment and 
worsened QST or NCS values. Three patients with stable IENFD also had stable 
peripheral neurological profiles; two of them had severely impaired renal function. 
 
Distal IENFD: No increase of IENFD was shown in any of the 11 patients. In four 
patients with increased proximal IENFD, two still showed reduction of distal IENFD. 
In two of the three patients with stable proximal IENFD, the distal value also reduced. 
Six patients had no distal innervation and one had a stable IENFD around 3 f/mm. 
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Table 5. Skin innervation and peripheral neurological profile in follow up patients. 
 
Sural nerve 
NCS  
QST IENFD Pt  Age  GFR Neuropathic 
pain 
complaints 
Hypohi
drosis 
SNAP 
(µV) 
NCV 
(m/s)
CDT WDT TSL Distal Proximal 
OT V1 22.2 150 Y N 47 30.3 ND ND ND 7.49 13.91 
 V2 23.3 107 Y b Y b 49 30.5 -13.6 9.97 12.93 5 22.46 
LK V1 46.3 103 Y N 46 16.4 -22 18 40 0 8.07 
 V2 47.3 111 Y N 44 16.5 -22 17 40 0 19.95 
RA V1 40.4 106 Y N 50 18.4 -22 18 32.73 1.13 12.9 
 V2 41.4 195 Yb N 47 17.8 -9.1 10.97 18.4 0.48 22.99 
KJ V1 40.4 10 Y Y 40 9.6 -15.17 4.23 16.43 0 10.45 
 V2 41.2 93 Y N 46 6.2 -22 3.8 33.13 0 11.44 
  V3 42 78 Y N 49 13.7 -5.07 7.37 18.57 0 18.97 
FA V1 53.9 14 Y Y 36 1.5 -22 17.1 40 0 10.8 
 V2 54.9 15 Y Y 41 3.81 -22 16.07 27.03 0 4.76 
KR V1 40.8 11 Y N 37 5.2 -11.87 18 11.63 0 21.29 
 V2 42 10 Y N 37 5.6 -22 16.7 38.47 0.58 13.64 
BD V1 29.7 58 Y Y  43 14.9 -22 3.87 27.93 2.58 37.2 
 V2 30.7 58 Y Y  44 12.8 -22 4.43 29.27 2.65 23.85 
KR V1 41.3 100 Y N 41 16.5 -17.17 5.1 16.67 0 22.29 
* V2 42.1 131 Y N 44 11 -12.2 9 36.57 0.17 9.18 
GR V1 45.8 44 Y N 52 11.7 -0.63 1.3 4.07 9.34 28.81 
 V2 46.8 56 Y N 56 35.4 -5.47 7.6 25.7 3.67 30.59 
TL V1 38.2 43 N N 57 19.4 -1.47 5.63 19.57 9.07 28.82 
 V2 39 48 N N 54 26.5 -3.87 4.63 19.83 5.23 30.59 
RG V1 36.4 71 Y Y 43 11.9 -7.43 12.97 13.17 0.95 14.99 
 V2 37.2 75 Y b Y 43 13 -15.6 5.13 15.9 1.64 16.41 
Red: reduced; Green: increased; Blue: stable; ND: not done 
* Note: this patient had proteinnuria 2000 mg/d.  
 
 
3.7 Subgroup analysis 
 
3.7.1 Patients with normal and patients with impaired renal function 
 
All the patients were divided into subgroups (Table. 6) based on their renal 
function (GFR ≥ 60 or < 60ml/min per 1.73 m2) and age (≥40 or <40 years). We 
 - 43 -
took patients younger than eighteen years as children. 
 
All the children (3 boys and 5 girls) had normal renal function. None of them 
had vital organ impairments, sign of depression, nor concomitant diseases. 
Skin biopsy was not performed with them, and no one received ERT.  
 
For patients under forty years, only two male and one female had severely 
impaired renal function. Both of these two male patients had cardiac problems 
and cerebral events and they showed indications of depression. The female 
patient displayed mild symptoms with a reduction of distal IENFD. All the three 
patients were on ERT.  
 
8 (10.5%) male and 6 (7.9%) female patients older than forty years had 
severely impaired renal function. Most of them had vital organ impairments and 
neuropathic pain. The female group showed a higher ECS-D score (23.7 +/- 
11.2 f/mm) than that of the male group (14.5 +/- 12.5 f/mm), though without 
statistic significance. Both the male (P<0.05) and female (P<0.05) groups had 
reduced distal IENFD, while the female group had a milder loss of innervation 
than male group (P<0.05). 7/8 male and 3/6 female patients were on ERT. 
 
In the group of patients with relatively normal renal function, 14 male and 16 
female patients were older than forty years. A majority of them had vital organ 
impairments. 9/14 male and 9/16 female patients complained of neuropathic 
pain, and both groups had ECS-D scores close to the diagnostic limit. The 
female group had less reduction of IENFD both proximally (27.8 +/- 8.1 f/mm) 
and distally (5.3 +/- 3.4 f/mm) than male patients (20.1 +/- 5.1 f/mm and 0.9 +/- 
1.0 f/mm respectively). 3/14 male and 8/16 female patients had concomitant 
diseases, while 10/14 male and 7/16 female patients were on ERT.  
 
10 male and 8 female patients younger than forty years had relatively normal renal 
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function. Approximately half of them had vital organ involvement. 9/10 male and 4/8 
female patients complained of neuropathic pain, and the male group showed 
indications of depression. The female group had a relatively normal innervation both 
proximally and distally, while the male group had a mild reduction of distal IENFD 
(4.8 +/- 2.7 f/mm). 2/10 male and 1/8 female patients had concomitant diseases. 
None of the female patients and eight of ten male patients were on ERT. 
 
Table 6. Patients with normal and impaired renal function.  
 
Male patients (n=39) Female patients (n=37) Parameters 
GFR<60 
(ml/min/1.73 m2) 
GFR≥60 
(ml/min/1.73 m2) 
GFR<60 
(ml/min/1.73 m2) 
GFR≥60 
(ml/min/1.73 m2) 
Age category  
(years) 
<18 18-
40 
≥40 <18 18-
40 
≥40 <18 18-
40 
≥40 <18 18-
40 
≥40 
Patients n 
(%) 
0 
 
2 
(2.6) 
8 
(10.5)
3 
(3.9) 
12 
(15.8)
14 
(18.4)
0 
 
1 
(1.3)
6 
(7.9) 
5 
(6.6) 
9 
(11.8) 
16 
(21.1)
Cardinal problem n 
(%) 
0 2 
(2.6) 
7 
(9.2) 
0 4 
(5.3) 
9 
(11.8)
0 0 5 
(6.6) 
0 
 
3 
(3.9) 
9 
(11.8)
Cerebral events n 
(%) 
0 2 
(2.6) 
2 
(2.6) 
0 1 
(1.3)
1 
(1.3)
0 0 1 
(1.3) 
0 0 1 
(1.3)
Neuropathic pain n 
(%) 
0 1 
(1.3) 
6 
(7.9) 
2 
(2.6) 
9 
(11.8)
9 
(11.8)
0 0 4 
(5.3) 
0 4 
(5.3) 
7 
(9.2) 
Pain score M 
(SD) 
 0 10.1
(4.3) 
1 8.9 
(7.1) 
6.5 
(6.1) 
 4 9.0 
(6.7) 
4.3 5.3 
(6.0) 
5.1 
(7.4) 
Disability score M 
(SD) 
 7.5 6.4 
(3.6) 
1 8.3 
(7.5) 
6.0 
(7.8) 
 0 11.5 
(10.1) 
0.8 2.4 
(3.5) 
5.3 
(8.9) 
CES-D score M 
(SD) 
 18.5 14.5
(12.5)
11 16.7
(6.2) 
15.9
(9.6) 
 10 23.7 
(11.2) 
13 10.8 
(6.1) 
13.1
(14.3)
Proximal IENFD (f/mm) M 
(SD) 
 36.6 7.6 
(8.7) 
 21.2 
(7.4) 
20.1 
(5.1) 
 30.6 
 
19.9 
 
 29.4 27.8 
(8.1) 
Distal IENFD (f/ mm) M 
(SD) 
 5.9 0.1 
(0.1) 
 4.8 
(2.7) 
0.9 
(1.0) 
 5.2 3.3 
 
 9.4 5.3 
(3.4) 
α-GAL activity <0.4 
nmol / min/mg protein 
n 
(%) 
0 
 
2 
(2.6) 
8 
(10.5)
3 
 
12 
(15.8)
14 
(18.4)
0 
 
1 
(1.3)
4 
(5.3) 
3 
(3.9) 
7 
(9.2) 
14 
(18.4)
Concomitant diseases 
n 
(%) 
0 1 
(1.3) 
2 
(2.6) 
0 2 
(2.6) 
3 
(3.9) 
0 0 6 
(7.9) 
0 1 
(1.3) 
8 
(10.5)
On ERT 
n 
(%) 
0 2 
(2.6) 
7 
(9.2) 
0 8 
(10.5)
10 
(13.1)
0 1 
(1.3)
3 
(3.9) 
0 0 7 
(9.2) 
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3.7.2 Female patients  
FD causes significant morbidity and mortality in affected males. As recently as 
2001, most FD females were thought to be asymptomatic throughout a normal 
life span or to develop only minor manifestations of the disease. As shown in 
Table 7 above, females with Fabry disease experienced intense neuropathic 
pain (n= 16); they also suffered from headache (n=5) and other pain (n=16), 
and pain produced comparable distress (n=11). 
Moreover, compared with the normal population, a much higher incidence of 
concomitant diseases was found in female patients older than 40 years. In this 
subgroup of 22 patients, 14 had diabetes, severe genitourinary system problems, 
thyroid disease, and other disorders. Among the 9 younger female patients 
under 40 years, only one had a concomitant disease. Such concomitant 
diseases also occurred in male patients, but with a far lower incidence (Fig. 12). 
Besides, of these 22 female patients older than 40 years, 6 had pathological 
renal function and 14 had cardiac involvement. However, compared with the ratio 
of 27/36 in male adult patients, only 11/32 female patients were under ERT.  
 
Figure 12. Perccentage of patients with concomitant diseases 
Thyroid: thyroid disease. Immunol: immunological disease. 
Chole: cholecystolithiasis. Genito-urol: genitourological disorder 
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3.7.3 Patients free from neurological complaints 
Eleven patients (4 male, 7 female) were free from any neurological complaints. 
Among them QST abnormalities were found in eight patients, in seven patients 
who had skin biopsies, six showed abnormalities (Table 7). Combined QST and 
skin biopsy revealed abnormalities in all these eleven patients.  
 
Table 7. QST and skin biopsy abnormalities in patients free from neurological complains.  
 
Pt Sex/ age QST abnormalities Skin biopsy abnormalities  
RD m/63 CDT↓, CPT↑, HPT↓ Not done 
IH m/63 Normal distal IENFD ↓ 
HP m/60 CDT↓, MPS↑ distal IENFD↓ 
MH m/46 CDT↓ Not done 
BT m/22 Normal Subepidermal innervation ↓ 
BH f/46 PHS↑ distal IENFD↓ 
TU f/44 CDT↓, TSL↑ distal IENFD↓ 
KL f/63 Normal distal and proximal IENFD↓ 
BA f/51 WUR↑ Normal  
NH f/49 MPS↑ Not done 
PP f/34 MPS↑ Not done 
 
 
3.7.4 Children with FD 
 
All the children (3 boys and 5 girls) had normal renal function, and none of them 
had vital organ impairments. Two of the three boys complained of 
acroparesthesia, two of the five girls had headache, the other patients were free 
from neuropathic pain. Healthy controls are under enrollment, and the QST 
analysis for children will be done in the near future.  
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3.8 Correlations 
    
GFR- Pain, disability and depression: In the female group, there was a 
correlation between GFR and the disability severity (p=0.031, r=-0.332), and 
depression symptoms (p=0.042, r=-0.305) but not between GFR and pain 
severity. There was no such correlation in the male group. 
 
GFR- IENFD: there was a strong correlation between GFR and distal IENFD in 
male patients (p<0.001, r=0.798), but not between GFR and proximal IENFD, 
neither in female patients.  
 
Age-IENFD: there was a strong correlation between age and distal IENFD in 
male patients (p<0.001, r=-0.726) and female patients (p=0.001, r=-0.688), but 
not between age and proximal IENFD, neither in female patients.  
 
CDT- IENFD: correlations between cold detection threshold (CDT) and distal 
IENFD were found in both the male (p=0.042, r= 0.329) and the female group 
(p=0.041, r= 0.413). No other correlation between QST and IENFD was found. 
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4. Discussion 
 
Our study achieved four main findings: First, for the first time, we found nerve 
regeneration in truncal skin may occur under ERT. Thus, the proximal IENFD 
might serve as a marker for the disease progression and its response to ERT in 
Fabry patients. Second, renal function plays an important role in small fiber 
function and its response to ERT. Third, such involvement of the peripheral 
nervous system (neuropathic pain, sensory function and IENFD) is age related. 
Fourth, female patients were less affected than male patients concerning small 
fiber involvement, but taking into account the involvement of other systems, the 
older female patients suffered from the disease as severely as male patients. 
 
Fabry disease is an X linked recessive inheritance with age related clinical 
features, among which neurological ones are the earliest to develop 20,61.To 
assess the small nerve fiber function, QST is currently widely used, and data 
analysis revealed that most thermal and mechanical thresholds increased with 
age 58. In addition, clinical trial results emphasize that baseline characteristics 
can substantially influence the outcome of ERT 34,35,54. We therefore divided our 
cohort into subgroups according to their age and GFR. GFR was chosen to 
reflect the renal and thus the overall condition of the patients，because the 
kidney is one of the most affected vital organs in Fabry patients and GFR is the 
most reliable and quantitative item which can serve as a baseline marker. We 
defined in this study the renal function as pathological when GFR was lower 
than 60ml/min per 1.73 m2, which is the borderline of Stage III chronic kidney 
disease 62. 
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4.1 Small fiber involvement and the role of renal function 
 
4.1.1 Neuropathic pain, pain related disability, and depression 
 
Peripheral neuropathy in patients with Fabry disease is axon length-dependent 
and characterized by selective involvement of small fibers 31,46,52, and 
neuropathic pain is the earliest symptom appeared in most Fabry patients. 
Although we screened only a limited number of children, there were no 
differences in the prevalence of neuropathic pain between children and adults, 
which was also reported by another group 40. Compared with adults, the 
children had less pain and none of them showed indication of depression. In 
adult patients, no difference of pain severity and pain related disability was 
found between older and younger male patients. While female patients younger 
than 40 years showed less pain, pain related daily disability, and depression 
than the corresponding male patients and female patients older than 40 years; 
such differences disappeared in older female patients. Contrary to the 
traditional view of females as carriers, female patients experienced intense 
disease-related pain and pain produced comparable distress, and seemed to 
be age-related, although such correlation was not statistically established. 
Although male patients had higher pain score, the interference of pain with daily 
life and mood was more obvious in female patients, which is corresponding with 
other reports 40, 63. 
 
GFR did not significantly affect pain in male patients. In women, correlations 
between GFR and the disability severity (p=0.031, r=-0.332), and depression 
symptoms (p=0.042, r=-0.305) were found, which indicate that renal function 
may play a role of pain related depression in female patients. Although pain 
perception is dependent on small fiber involvement, our study could not detect 
any correlation between pain, QST profile, and IENFD in any group of patients. 
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4.1.2 QST and small fiber function 
 
A significantly increased cold detection threshold (CDT, indicating loss of 
sensory function for cold stimuli) was found in male patients older and younger 
than 40 years, while unmyelinated C-fiber -mediated warm detection thresholds 
were often within the normal range. That cold perception is more frequently and 
severely impaired than warm perception in male patients was also reported 
previously 31,64,65. We also found correlations between CDT and distal IENFD 
both in male (p=0.04, r= 0.329) and female patients (p=0.04, r= 0.413). No 
other correlation between QST and IENFD was found. Based on these findings, 
there might be a more pronounced loss of Aδ-fibers than C-fibers in Fabry 
disease. In our study, PGP 9.5 antibody was used. It is a polyclonal panaxonal 
marker that stains both Aδ- and C-fibers, and currently the most commonly 
used marker for IENFD studies. Although CGRP and Substance P are specific 
antigens for C-fibers 66,67, the fact that many patients had only very low IENFD 
or even no innervation prevented us from specifying the fiber losses. We 
speculate that the GL-3 deposits in the cell bodies and axons of A  fibers and 
in the adaxonal cytoplasm of the surrounding Schwann cells might lead to more 
severe functional loss than the unmyelinated axons of C fibers 46,68.  
 
Besides increased CDT, significantly increased thermal sensory limen (TSL) 
and decreased vibration detection threshold (VDT) were found in male patients 
younger than 40 years, which were also signs indicating loss of sensory 
function of C- and Aß- fibers respectively. This finding indicates that sensory 
function disturbance developed when patients were still young and maybe due 
to the fact that most thermal and mechanical thresholds increased with age 58, 
the differences of sensory function and the corresponding QST values might 
not be obvious at an older age. 
 
In male groups, compared to patients with relatively normal renal function, 
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patients with pathological renal function had increased dynamic mechanical 
allodynia (DMA) indicating a peripheral and central sensitization. Dynamic 
mechanical allodynia is the pain due to a light moving mechanical stimulus, and 
occurs in subgroups of patients with peripheral or central neuropathic pain. 
Both peripheral and central nervous system mechanisms have been implicated 
in the generation of DMA. In subgroups of patients with post-herpetic neuralgia 
peripheral sensitization of nociceptive afferents have been suggested as a 
basis for dynamic mechanical allodynia 69, while Baron et al. argue that this 
symptom may be due to secondary changes in the central nervous system 
processing that might strengthen the synaptic ties between A beta-fibers and 
central nociceptive pathways and not necessarily related to ongoing 
nociceptive C-fiber input 70. In our study, there was more severe small fiber loss 
in patients with pathological renal function. We hypothesize that more severely 
damaged small fibers may indicate more disturbed function or damage of the 
neurons both peripherally and centrally, so besides the small fiber dysfunction, 
the secondary central hyperexcitability might contribute to the DMA in patients 
with pathological renal function. 
 
Of 32 adult female patients, 29 had abnormal QST values, but only 4 patients 
had reduced CDT. A recent study reported that 25% of female patients had 
abnormal CDT in the foot 51, the small sample (n=12) of their study may count 
for this discrepancy. Generally, although female patients also suffer from severe 
neuropathic pain, especially in older group, the small nerve fibers are less 
affected, which supports our finding that there is a lack of correlation between 
pain and QST profile in Fabry patients. Patients with pathological renal function 
seemed to have decreased thermal detection threshold compared to patients 
with normal renal function, although not statistically significant, which also in 
accord with our finding that female patients are less affected concerning small 
fiber function.  
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4.1.3 Skin innervation (IENFD) in FD  
 
Since standard nerve-conduction studies and large nerve biopsy results are 
typically normal in small-fiber neuropathy, the investigation of intraepidermal 
nerve fibers is widely used for the diagnosis of small-fiber neuropathy including 
FD related neuropathy 53,71,72. Compared to our laboratory’s normal values for 
Th12 and the lower leg, the intraepidermal innervation density was significantly 
reduced in male patients (18.0 +/- 8.8 fibers/mm proximally and 2.2+/-2.8 
fibers/mm distally), and mildly reduced in female patients (26.2 +/- 9.9 
fibers/mm proximally and 6.3 +/- 4.3 fibers/mm distally). In male patients a 
severe loss of intraepidermal innervation at the ankle but less severe at the 
distal thigh has been described 52,53,64, which is in line with our findings. The 
reduced density of the subepidermal nerve plexus was also more frequent in 
male patients. Unlike the other vital organ involvement which affected females 
as severely as males in the groups older than forty years, the small fiber loss is 
more severe in males than in females in all age groups. Although female 
patients also suffer from severe neuropathic pain, especially in the older group, 
the loss of small nerve fibers was less severe, which is consistent with our 
findings in the QST profile and the lack of correlation between pain and IENFD 
in Fabry patients. However, strong correlations between age and distal but not 
proximal IENFD were found both in male (p=0.000, r=-0.726) and female 
patients (p=0.001, r=-0.688), which is also the case with healthy people 73,74 
and is consistent with the fact that most thermal and mechanical thresholds 
increased with age 58. 
 
In male patients there was a strong correlation between GFR and distal IENFD 
(p=0.000, r=0.798). Such a correlation was not found in the female group, the 
possible reason is that in the 19 female patients who had the skin biopsies, only 
three had pathological renal function. Clinical trials have shown that patients 
with impaired renal function at baseline have a less favorable outcome and may 
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develop renal progression despite treatment with ERT 34. Guidelines for the 
treatment of Fabry disease are being developed but currently not uniformly 
applied 75, and the initiation of ERT is based mainly on the clinical course of the 
disease, in particular the vital organ events 76. Our findings indicate that 
combined together, GFR and IENFD may serve as useful items in the decision 
when to start ERT and other comprehensive treatment to prevent the 
irreversible nerve damage. 
 
Strong correlations between age and distal IENFD were found both in male 
(p<0.001, r=-0.726) and female patients (p<0.001, r=-0.688). In healthy people, 
most thermal and mechanical thresholds increased with age 58, while the distal 
IENFD decreased with age 73,74.  Such trends were also found in our Fabry 
patients.  
 
 
4.2 Hypohidrosis, auditory impairment, and CNS symptoms 
 
Hypohidrosis was present in 18.4% male and 6.5% female patients in our 
cohort. The incidence of such a classic symptom of FD has been previously 
reported with high variances from 52% to 93% in male and from 1% to 32.8% in 
female patients 77-79.  
 
Audiovestibular symptoms were reported to be present in 57-80% of male and 
11-85% female patients 20,21,77,80, such a high incidence was not found with our 
patients, but the more precise instruments and examination applied in the 
published reports may account for this discrepancy. Hypohidrosis and 
audiovestibular symptoms are more frequent in male patients than female 
patients, which is in accord with our own findings. Another finding in our 
subgroups was that patients older than 40 years had a higher incidence of 
auditory impairment in both the male and female groups. For CNS, 18.4% 
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patients had a history of cerebral events, but only 2 suffered from neurological 
sequelae. Since we did not focus on the CNS, only routine extra- and 
transcranial Doppler sonography was applied and it gave normal results in all 
patients. 
 
The failure of Doppler to detect the possible abnormality of CNS in Fabry 
patients indicates that the deposit of GL-3 in the CNS may not necessarily lead 
to pathological global and local cerebral blood flows (CBF) which also reported 
in an animal study 81. Probably, more precise methods are needed to measure 
subtle abnormalities.  
 
 
4.3 Response of peripheral nervous system to ERT and the role of renal 
function 
 
Before 2001, only symptomatic treatments (e.g., analgesics, dialysis, and 
kidney transplantation) were available to patients with FD. Since then, the 
development of ERT represents a major therapeutic breakthrough. The results 
of initial clinical trials of agalsidase beta showed clearance of GL-3 in multiple 
dermal cell types, less pain, and functional improvement of different nerve 
fibers 29,31,45. However, a better understanding of the long-term neurologicall 
benefits that can be expected from ERT remains essential. 
 
In our cohort, 21 patients (17 male and 4 female) were divided into subgroups 
according to their renal function for the follow up study. 17 male and 2 of female 
patients were on ERT, 2 female patients with mild symptoms were taken as 
untreated controls. 
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4.3.1 Skin innervation (IENFD) and proximal regeneration 
 
In recent years, serial punch skin biopsy and IENFD analysis has been proved 
useful to document disease-modifying treatment effects in peripheral 
neuropathy 53,82,83. Many Fabry patients, especially males have very low IENFD 
or even no innervation in the distal leg. Moreover, none of our 11 follow up 
patients who had repeated skin biopsies showed increased distal IENFD, which 
was also reported by Schiffmann’s group 53. We therefore looked into a 
proximal site with a higher baseline of IENFD, and intriguingly we found 
proximal regeneration in four patients. Previous studies on regeneration did not 
give consistent results. Trials using local denervation showed regeneration in 
both healthy people and patients with neuropathy; while the rate of regenerative 
sprouting was significantly lower in patients with neuropathy and significantly 
associated with the baseline IENFD 83-85. On the other side, serial skin biopsies 
from Fabry patients under ERT revealed no regeneration even after long term 
treatment 53. Although in cases when the scar from previous biopsy was not 
obvious, the repeated biopsy site was empirically decided by the operator and 
this may likely cause a systematic error, our finding is reliable since good 
reproducibility of biopsies taken from adjacent sites has been shown in normal 
controls and patients with neuropathy 84,86. We hypothesize that regeneration 
was apt to occur proximally but not distally in Fabry patients. The possible 
reason may be that at the Th12 level, there are more intact nerve fibers and 
high baseline IENFD, and thus higher levels of trophic support. Moreover, in 
this length dependent neuropathy of FD, the accumulation of GL-3 in the dorsal 
root ganglia 41,87, although it may get somehow cleared under ERT, might still 
result in a limited ability to maintain the metabolic demands of proximal 
regeneration but fail to keep up with the necessary demands of distal 
regeneration. Functional disturbance in Fabry patients not being reversed 
despite clearance of GL-3 was reported in other vital organ involvements 28,60. 
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In this study we tested the hypothesis that proximal IENFD can serve as a 
marker for the response of the peripheral nervous system to ERT in Fabry 
patients. Studies of other vital organs involvement in Fabry patients have shown 
that patients with initially impaired renal function have continued deterioration in 
renal function and had 12 clinical events over the course of treatment despite 
adequate substrate clearance 34,60. A study of the ERT effect on cardiac 
morphology, function, and late enhancement (LE) showed that only patients 
without LE at baseline had significant reductions in left ventricular mass during 
ERT and had an improvement of regional myocardial function 35. In our study, of 
the 11 patients who had the repeated biopsy, the four who had increased 
proximal IENFD from 11.3 f/mm to 21.1 f/mm also had improvement in 
acroparesthesia and other pain, regained the ability to perspire and had better 
tolerance of heat. They also had improved values in QST and 
neurophysiological examination. Four patients had reduced IENFD, and also 
worsened QST or NCS values. Three patients with stable IENFD had relatively 
stable peripheral neurological profiles. These results support our hypothesis 
that proximal IENFD can serve as a marker for the peripheral nervous systems’ 
response to ERT. Another important finding is that all the four patients with 
increased IENFD had relatively normal renal function, including one patient with 
twice renal transplantation. Four patients with reduced IENFD and two of the 
three patients with stable IENFD had severe renal impairment. Such role of 
renal function on distal IENFD in Fabry patients has also been reported by other 
groups 52,53. Although the number is relatively small, these cases proved that 
proximal IENFD can serve as a marker for the progression of Fabry disease 
and its response to ERT.  
 
Moreover, renal function is an important factor that influences the ERT effect on 
the peripheral nervous system. Another thing need to be mentioned is that 
patients with severe renal impairment can still benefit from ERT if they have a 
relatively stable proximal IENFD.  
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4.3.2 QST follow up 
 
Of 19 patients (17male, 2 female) who were on ERT, improved values of CDT 
were found in 4 patients, improved WDT and CPT was found in 4 and 1 patient 
respectively. Although considerably overall thermal sensory improvement was 
found in one patient (Fig. 8), patients with relatively normal renal function 
showed a generally stable QST profile. Initial clinical trials applying QST have 
shown more obvious improved function of C-, A -, and Aß-nerve fibers and 
intradermal vibration receptors 31. Compared with our patients (40.4 ± 8.0 
years), the fact that the patients they enrolled were much younger (27.9 ± 8.0 
years) and received ERT at earlier age may attribute to this difference. Another 
trial showed that prolonged ERT in Fabry disease leads to a modest 
improvement of cold and warm sensation in the foot 48, which is corresponding 
to our findings. 
 
For the first time we reported the effect of renal function on the sensory function 
in Fabry patients. Six patients with severely impaired renal function showed a 
deteriorated QST profile despite of ERT. In a long term ERT study 54, all 12 
clinical events occurred in patients with initially impaired renal function in whom 
renal function continued to deteriorate and whose left ventricular posterior wall 
thickness did not improve over the course of treatment. An 18-months trial of 
ERT showed decreased IENFD at distal thigh, and that renal function and 
uremic neuropathy likely contributed to the decline 53. Interestingly, three of the 
seven male patients who had QST for the third time (Table 5) showed improved 
TSL, and two of these three patients had pathological renal function. One had a 
GFR only around 15ml/min per 1.73 m2, and the other has had a second renal 
transplantation but with an improved GFR from 10 to 78 ml/min per 1.73 m2.  
That the overall QST profile of the six two-year follow up patients showed some 
deterioration might indicate the importance of a early start of ERT. Our study 
revealed that renal function plays important role on the sensory function and its 
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response to ERT in Fabry patients, which is consistent with its role on IENFD. 
Although impaired renal function did not preclude sensory improvement under 
ERT, it made it less successful.  
 
Among the patients with improved thermal detection, some of them had 
reduced distal IENFD or even no innervation. There might be several 
explanations for this discrepancy. First, it has been shown in various studies 
that the thermal QST results do not correlate well with IENFD in Fabry patients 
51,53. Second, the skin biopsy site is not identical with the QST site. Although the 
IENFD at distal leg is reliable to reflect the innervation at the dorsal side of foot 
where the QST is performed, the area of the QST site is much larger than that 
of the punch biopsy site and therefore may address more fibers. Third, besides 
the cutaneous nerve fiber endings, the fibers in the dermis and even deeper 
layers may also contribute to the thermal perception.  
 
 
4.3.3 Neuropathic pain and other manifestations  
 
In our 19 follow up patients on ERT, ten patients reported less severe 
acroparesthesia or showed improved pain and pain related inability score, 
including three patients with pathological renal function. However, the pain and 
pain related disability scores increased in 11 patients. The CES-D scores also 
increased in 15 patients, indicating more severe depression. Even in three 
patients whose pain and pain related disability scores obviously decreased, 
CES-D still increased. This may be due to psychological factors: knowing that 
the disease is a life-long process, fear of pain onset, ERT infusion burden, etc. 
Patients may need more psychological help than hitherto thought.  
 
Four patients reported better perspiration, including two patients with impaired 
renal function. Seven patients showed improved sural nerve NCS, and no 
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patient had a CNS event or worsening of cerebral blood flow parameters during 
the follow up observation. Involvement of the peripheral nervous system 
affected mainly small A - and C- fibers, and hypohidrosis and other 
abnormalities attributed to autonomic nervous system dysfunction. 
Improvement in pain, sweating and small fiber function has also been noted 
following ERT by other groups 31,45,48. 
 
 
4.4 QST and skin biopsy as early diagnostic methods 
 
Although the characteristic pain may be first noted in childhood or adolescence, 
patients may not be diagnosed until adulthood, because physicians often do not 
attribute these signs and symptoms to FD, but misdiagnose them as other more 
common disorders, such as rheumatoid or juvenile arthritis, rheumatic fever, 
“growing pains” and etc 88. In our 68 adult Fabry patients, most had peripheral 
nerve symptoms, and QST abnormalities were found in all of them. 11 patients 
were totally free from neurological complains, but if QST was combined with 
skin biopsy, abnormalities were revealed in all of them. Fabry disease is a 
progressive disorder; therefore it is important that patients should be identified 
as early as possible. While the clinical diagnosis of small-fiber neuropathy is 
difficult, the diagnostic yield can be increased using a combination of thermal 
QST and IENFD measurements, which was also reported by another group 51. 
 
 
4.5 Female patients and concomitant diseases 
 
Contrary to the traditional view of females as carriers, females with Fabry 
disease experienced intense disease-related acroparesthesia and other pain, 
also pain produced considerable distress, which was also shown in other 
surveys 63,89. In our cohort, female patients younger than 40 years showed less 
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pain, pain related daily disability and depression than the corresponding male 
patients and female patients older than 40 years; while such differences 
disappeared in older female patients. Moreover, in patients older than 40 years, 
the frequency of impairment of vital organs is similar between males and 
females. Furthermore, female patients older than 40 years suffered from a high 
number of comorbidities. Fewer than half of these patients were receiving ERT. 
Such comorbidities contribute considerably to their loss of quality of life. 
Deegan et al 61 reported age related clinical features in female Fabry patients, 
and we hypothesize that there is also an intimate relation between age and 
concomitant disease, especially in female Fabry patients. We conclude that 
more attention and early intervention should be given to female patients to 
prevent the onset of the later manifestations of the disorder. 
 
 
4.6 Conclusion 
 
Both male and female patients with FD suffer from severe neuropathic pain. 
The small A - and C- fiber loss visualized by skin biopsy and the sensory 
function impairment manifested by QST profile is more severe in male than 
female patients. Renal function plays an important role on the disease 
progression and its response to ERT. Patients with normal renal function have a 
better chance to benefit from ERT. Proximal IENFD can serve as a marker for 
ERT effect on peripheral nervous system in Fabry patients. Patients with 
severely impaired renal function can still benefit neurologically from ERT when 
they had a stable proximal IENFD. Despite of the reduction in neuropathic pain 
and the improvement in thermal sensation and sweating following ERT in some 
patients, taking all follow up patients as a whole group, ERT did not normalize 
the function of the peripheral nervous system. Consequently, it appears logical 
to consider ERT as a preventive treatment that should be started as early as 
possible before irreversible damage has occurred. 
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Probably due to psychological factors, some patients showed indications of 
more depression although they reported less pain with ERT. More 
psychological help should be given. While the clinical diagnosis of small-fiber 
neuropathy is difficult, the diagnostic yield can be increased using a 
combination of thermal QST and IENFD measurements. Besides pain and vital 
organ involvement, female patients older than 40 years suffered from a high 
number of comorbidities. Therefore more attention and early intervention 
should be given to female patients. In addition to ERT, comprehensive 
management of the disease is mandatory.  
 
It is mandatory to collect further information in our future study to verify the role 
proximal IENFD plays as a mark for the disease progression and the ERT effect. 
Peripheral neural function needs to be looked into in more pediatric patients. 
Since some patients with similar baseline characters showed different response 
to ERT, the relation between genotype and phenotype should be studied.  
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Summary 
 
Fabry’s disease (FD) is a rare inherited X-linked lysosomal storage disease 
caused by deficient or absent activity of the enzyme α-galactosidase A (α-GAL) 
due to mutations in the GLA-gene. This leads to the systemic accumulation of 
glycosphingolipids (mainly GL- 3) in multiple organs and tissues, including the 
central and peripheral nervous system.  Fabry patients often suffer from 
small-fiber neuropathy, pain attacks, and from burning pain of the hands and 
feet. Previously, a reduction in pain, an increase in small nerve fiber function 
and an improvement in sweat gland function, but not an increase in skin 
innervation have been shown under enzyme replacement therapy (ERT). 
 
The aim of this study was to longitudinally investigate the neurological function 
in Fabry patients, with special emphasis on the peripheral nervous system. A 
cohort of 76 patients (39 men and 37 women) with FD was prospectively 
recruited and studied by clinical neurological examination, neurophysiology, 
quantitative sensory testing (QST), Doppler sonography, and skin punch biopsy 
from the lower leg and lower back with quantification of the intraepidermal 
innervation. Median follow up was 1.1 years (range 0-2.8 years).  
 
Our study achieved four main findings: First, for the first time, we could show 
that ERT induced epidermal nerve regeneration in proximal skin. Thus, 
proximal intraepidermal nerve fiber density (IENFD) might serve as a marker for 
the disease progression and its response to ERT.  
 
Second, renal function played an important role in small fiber function and its 
response to ERT. Correlations between the glomerular filtration rate (GFR) and 
pain were found in female patients, and a correlation between GFR and distal 
IENFD was found in male patients. In the follow-up study, patients with normal 
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renal function had a better chance to increase their IENFD under ERT. 
 
Third, abnormal QST values and an IENFD reduction were present in some 
otherwise asymptomatic patients. Small fiber involvement (neuropathic pain, 
sensory function and IENFD) in FD was age related. 
 
Fourth, female patients were less affected than male patients concerning small 
fiber involvement, but vital involvement and comorbidities increased with age in 
female patients. Thus, this patient group deserves special attention. 
 
In conclusion, a reduction in skin innervation is a very early sign of nervous 
system involvement in patients with FD and should be carefully monitored. 
Peripheral nerve regeneration is possible in patients with FD under ERT, and is 
best in patients with normal renal function. The mechanisms of the typical pain 
suffered by Fabry patients are as yet unclear and deserve further studies. 
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Appendix  
 
A. NPSI 
 
FRAGEBOGEN NEUROPATHISCHE SCHMERZEN 
 
 
Datum: …………….. 
 
Vorname: …………………………………… Name: ………………………………………. 
 
Geschlecht: …………………….. 
 
Alter: …………………… 
 
 
Sie leiden an Schmerzen.  
Möglicherweise haben Sie so genannte Spontanschmerzen, die ohne einen erkennbaren Auslöser 
auftreten. Diese sind entweder dauerhaft, d.h. ohne Unterbrechung ständig vorhanden, treten mit 
Unterbrechungen auf und/oder schwanken in ihrer Stärke. Zum besseren Verständnis haben wir 
versucht, dies anhand der folgenden Bilder deutlich zu machen: 
 
 
 
 
 
 
Dauerschmerzen  
mit leichten 
Schwankungen 
Dauerschmerzen  
mit starken 
Schwankungen 
Schmerzattacken 
(unterbrochener 
Schmerz) 
dazwischen 
schmerzfrei 
Schmerzattacken 
(unterbrochener 
Schmerz) 
auch dazwischen 
Schmerzen 
 
Vielleicht haben Sie auch Schmerzen, die durch bestimmte äußere Auslöser (Berührung, Druck, 
Kälte) hervorgerufen werden können.  
Bei einem Patienten können gleichzeitig mehrere Arten von Schmerzen bestehen.  
 
Schmerzen sind für Patienten oft schwer zu schildern und Ärzte haben häufig Schwierigkeiten diese 
richtig zu verstehen. Deswegen werden Fragebögen entwickelt, die den Ärzten helfen sollen, die 
Schmerzen ihrer Patienten auch im Einzelnen zu erfassen. Dieses ist ein neuartiger Fragebogen, 
dessen Nützlichkeit wir testen wollen. Dazu benötigen wir Ihre Hilfe. 
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Wo haben Sie Schmerzen ? 
 
Vorab möchten wir Sie fragen, wo überall Sie unter Schmerzen leiden. 
 
Malen Sie bitte in den nachfolgenden Körperschemata ein, wo Sie überall Schmerzen haben. 
Bitte kennzeichnen Sie das ganze Schmerzgebiet (durch Schraffierung mit Bleistift oder 
Kugelschreiber), damit wir wirklich wissen, wo Sie überall Schmerzen haben. 
 
 
 
Nehmen Sie Medikamente? 
 
Haben Sie in den letzten 24 Stunden Medikamente gegen Ihre Schmerzen genommen? 
 
 ja     nein 
 
Welche Medikamente haben Sie in den letzten 24 Stunden gegen Ihre Schmerzen genommen? 
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Name des Medikaments 
Wie oft haben Sie 
das Medikament 
genommen? 
Wie viele Tabletten/ 
Tropfen /Zäpfchen 
haben Sie genommen?
z.B. Paracetamol 500 mg 2 mal jeweils 2 Tabletten 
   
   
   
 
Sie werden, wie Sie es vielleicht schon aus anderen Fragebogen kennen, nach der Stärke ihrer 
Beschwerden gefragt. Da man die Stärke von Beschwerden nicht einfach messen kann, verwenden 
wir hier eine Skala von 0 bis 10. 0 bedeutet dabei immer, dass Sie die entsprechenden Beschwerden 
nicht haben. 10 bedeutet, dass Sie die Beschwerden in der für Sie schlimmsten vorstellbaren Stärke 
haben.  
 
Spontanschmerzen 
 
 
Die ersten Fragen beziehen sich nur auf Spontanschmerzen, d.h. solche Schmerzen die ohne 
äußere Auslöser auftreten.  
Haben Sie Spontanschmerzen, d. h. Schmerzen, die ohne äußeren Auslöser auftreten? 
 
Bitte kreuzen Sie für jede der folgenden Fragen die Ziffer an, die am besten der Stärke Ihrer 
Spontanschmerzen im Mittel über die letzten 24 Stunden entspricht. Kreuzen Sie „0“ an, wenn 
Sie diese Art Schmerz nicht verspürt haben. (kreuzen Sie bitte immer nur eine Ziffer an) 
 
Q1. Ist Ihr Schmerz brennend? 
 kein Brennen 0 1 2 3 4 5 6 7 8 9 10 schlimmstes vorstellbares 
Brennen 
 
Q2. Fühlt sich Ihr Schmerz an wie eingeschnürt oder wie in einem Schraubstock eingeklemmt zu 
sein? 
kein  
Einschnüren 
0 1 2 3 4 5 6 7 8 9 10 schlimmstes vorstellbares 
Einschnüren 
 
Q3. Fühlt sich Ihr Schmerz wie ein Druck an? 
kein Druck 0 1 2 3 4 5 6 7 8 9 10 schlimmster vorstellbarer 
Druck 
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Q4. Wie lange dauerten Ihre Spontanschmerzen in den letzten 24 Stunden?  
Kreuzen Sie die Antwort an, die der Dauer am besten entspricht:  
 dauerhaft (mehr als 12 Stunden)  
 zwischen 8 und 12 Stunden  
 zwischen 4 und 7 Stunden   
 zwischen 1 und 3 Stunden  
 weniger als 1 Stunde  
 
Schmerzattacken / unterbrochener Schmerz 
 
 
Beschreibt eines der beiden Bilder die Schmerzen, wie Sie sie verspüren? 
 
 
 
 
 
 
 
 
 Schmerzattacken 
(unterbrochener 
Schmerz) 
dazwischen schmerzfrei
Schmerzattacken 
(unterbrochener 
Schmerz) 
auch dazwischen 
Schmerzen 
 
 
 
 
Für jede der folgenden Fragen kreuzen Sie bitte die Ziffer an, die am besten die mittlere Stärke 
Ihrer Schmerzattacken während der letzten 24 Stunden angibt. Kreuzen Sie „0“ an, wenn Sie 
einen solchen Schmerz nicht verspürt haben. (kreuzen Sie bitte immer nur eine Ziffer an) 
 
 
Q5. Empfinden Sie Ihre Schmerzattacken wie elektrische Schläge? 
überhaupt nicht 0 1 2 3 4 5 6 7 8 9 10 schlimmste vorstellbare 
elektrische Schläge 
 
 - 68 - 
 
Q6. Fühlt sich Ihr Schmerz stechend an?  
kein Stechen      0 1 2 3 4 5 6 7 8 9 10 schlimmstes 
vorstellbares Stechen 
 
 
Q7. Wie viele dieser Schmerzattacken hatten Sie in den letzten 24 Stunden? 
Wählen Sie die Antwort, die am ehesten zutrifft: 
 mehr als 20  
 zwischen 11 und 20   
 zwischen 6 und 10  
 zwischen 1 und 5  
 keine Schmerzattacken  
 
Schmerzen, die durch bestimmte Auslöser hervorgerufen oder verschlimmert 
werden 
 
 
Haben Sie Schmerzen, die durch bestimmte Auslöser hervorgerufen oder verschlimmert werden, z. 
B. durch Reiben, Druck, oder Kontakt mit kalten Gegenständen im schmerzhaften Bereich? 
 
 
Für jede der folgenden Fragen kreuzen Sie bitte die Ziffer an, die am besten der Stärke der 
Schmerzen, die durch Auslöser hervorgerufenen oder verschlimmerten entspricht, die Sie im Mittel 
in den letzten 24 Stunden hatten. Kreuzen Sie „0“ an, wenn Sie diesen Typ Schmerz nicht verspürt 
haben. (kreuzen Sie bitte immer nur eine Ziffer an) 
 
Q8. Haben Sie im schmerzhaften Bereich Schmerzen, die durch Reiben hervorgerufen oder 
verschlimmert werden? 
 
kein Schmerz     0 1 2 3 4 5 6 7 8 9 10 maximal vorstellbarer 
Schmerz 
 
Q9. Haben Sie Schmerzen, die durch Druck auf den schmerzhaften Bereich hervorgerufen werden? 
kein Schmerz     0 1 2 3 4 5 6 7 8 9 10 maximal vorstellbarer 
Schmerz 
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Q10. Haben Sie Schmerzen, die durch Kontakt mit einem kalten Gegenstand im schmerzhaften 
Bereich hervorgerufen oder verschlimmert werden? 
kein Schmerz     0 1 2 3 4 5 6 7 8 9 10 maximal vorstellbarer 
Schmerz 
 
 
Gefühlsstörungen 
 
 
Haben Sie im schmerzhaften Bereich ungewöhnliche Gefühlsstörungen?  
 
 
Für jede der folgenden Fragen kreuzen Sie bitte die Ziffer an, die am besten der Stärke Ihrer 
ungewöhnlichen Gefühlsstörungen entspricht, die Sie durchschnittlich in den letzten 24 
Stunden hatten. Kreuzen Sie „0“ an, wenn Sie dieses Gefühl nicht hatten (kreuzen Sie immer nur 
eine Ziffer an). 
 
Q11. Empfinden Sie ein Kribbeln? 
kein Kribbeln      0 1 2 3 4 5 6 7 8 9 10 maximal vorstellbares 
Kribbeln 
 
Q12. Empfinden Sie etwas, das sich anfühlt wie Ameisenlaufen? 
kein 
Ameisenlaufen    
0 1 2 3 4 5 6 7 8 9 10 maximal vorstellbares 
Ameisenlaufen 
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B. GCPS 
 
Schmerzfragebogen (GCPS) 
 
Wie würden Sie Ihren Schmerz jetzt im Augenblick auf einer Skala einschätzen, wenn 0 = kein 
Schmerz und 10 = stärkster vorstellbarer Schmerz bedeuten? Bitte markieren Sie die für Sie 
zutreffende Zahl: 
 
0 –– 1 –– 2 –– 3 –– 4 –– 5 –– 6 –– 7 –– 8 –– 9 –– 10 
kein 
Schmerz 
       stärkster 
vorstell-barer 
Schmerz 
 
Wie stark war der stärkste Schmerz in den letzten 4 Wochen, wenn 0 = kein Schmerz und 10 
= stärkster vorstellbarer Schmerz bedeuten?  
 
0 –– 1 –– 2 –– 3 –– 4 –– 5 –– 6 –– 7 –– 8 –– 9 –– 10 
kein 
Schmerz 
       stärkster 
vorstell-barer 
Schmerz 
 
Wie stark war der Schmerz in den letzten 4 Wochen im Durchschnitt, wenn 0 = kein Schmerz 
und 10 = stärkster vorstellbarer Schmerz bedeuten?  
 
0 –– 1 –– 2 –– 3 –– 4 –– 5 –– 6 –– 7 –– 8 –– 9 –– 10 
kein 
Schmerz 
       stärkster 
vorstell-barer 
Schmerz 
 
 
An wie vielen Tagen der letzten 4 Wochen konnten Sie aufgrund der Schmerzen nicht Ihren 
üblichen Aktivitäten nachgehen (z.B. Arbeit, Schule, Haushalt, Hobby)?  
 
an                        Tagen  
 
 
In welchem Maße haben Schmerzen Ihre alltäglichen Aktivitäten (Ankleiden, Waschen, 
Essen, Einkaufen etc.) in den letzten 4 Wochen beeinträchtigt, wenn 0 = keine 
Beeinträchtigung und 10 = keine Aktivitäten mehr möglich bedeuten?  
 
0 –– 1 –– 2 –– 3 –– 4 –– 5 –– 6 –– 7 –– 8 –– 9 –– 10 
keine 
Beeinträchtigung 
      keine Aktivität 
mehr möglich 
 
Wie sehr haben Ihre Schmerzen während der letzten 4 Wochen Ihre Freizeitaktivitäten oder 
Unternehmungen im Familien - und Freundeskreis beeinträchtigt, wenn 0 = keine 
Beeinträchtigung und 10 = keine Aktivitäten mehr möglich bedeuten?  
 
0 –– 1 –– 2 –– 3 –– 4 –– 5 –– 6 –– 7 –– 8 –– 9 –– 10 
keine 
Beeinträchtigung 
      keine Aktivität 
mehr möglich 
 
In welchem Maße haben Ihre Schmerzen während der letzten 4 Wochen Ihre Arbeitsfähigkeit 
(einschließlich Hausarbeit) beeinträchtigt, wenn 0 = keine Beeinträchtigung und 10 = keine 
Aktivitäten mehr möglich bedeuten?  
 
0 –– 1 –– 2 –– 3 –– 4 –– 5 –– 6 –– 7 –– 8 –– 9 –– 10 
keine 
Beeinträchtigung 
      keine Aktivität 
mehr möglich 
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C. ADS 
 
 
Bitte kreuzen Sie bei den folgenden Aussagen die Antwort an, die Ihrem Befinden während der letzten  
Woche am besten entspricht / entsprochen hat.  
Antworten:  selten  = weniger als 1 Tag oder überhaupt nicht  
  
manchmal  = 1 bis 2 Tage lang    
öfters  = 3 bis 4 Tage lang    
meistens  = die ganze Zeit (5 bis 7 Tage lang)    
Während der letzten Woche ...  selten  manchmal  öfters  meistens 
1. ... haben mich Dinge beunruhigt, die mir sonst nichts 
ausmachen. ...........  ..........  .........  .......... ......... 
2. ... hatte ich kaum 
Appetit. .........................................................................  ..........  .........  .......... .......... 
3. ... konnte ich meine trübsinnige Laune nicht loswerden, obwohl     
mich meine Freunde/Familie versuchten aufzumuntern........................ ..........  .........  .......... .......... 
4. ... kam ich mir genauso gut vor wie 
andere...............................................  ..........  .........  .......... .......... 
5. ... hatte ich Mühe, mich zu 
konzentrieren..................................................  ..........  .........  .......... .......... 
6. ... war ich deprimiert / 
niedergeschlagen...................................................  ..........  .........  .......... .......... 
7. ... war alles anstrengend für 
mich. ............................................................  ..........  .........  .......... .......... 
8. ... dachte ich voller Hoffnung an die 
Zukunft.............................................  ..........  .........  .......... .......... 
9. ... dachte ich, mein Leben ist ein einziger 
Fehlschlag. ..............................  ..........  .........  .......... .......... 
10. ... hatte ich 
Angst......................................................................................  ..........  .........  .......... .......... 
11. ... habe ich schlecht 
geschlafen. ...............................................................  ..........  .........  .......... .......... 
12. ... war ich fröhlich 
gestimmt. .....................................................................  ..........  .........  .......... .......... 
13. ... habe ich weniger geredet als 
sonst. ......................................................  ..........  .........  .......... .......... 
14. ... fühlte ich mich 
einsam..........................................................................  ..........  .........  .......... .......... 
15. ... waren die Leute unfreundlich zu 
mir. ....................................................  ..........  .........  .......... .......... 
16. ... habe ich das Leben 
genossen...............................................................  ..........  .........  .......... .......... 
17. ... mußte ich 
weinen. ................................................................................  ..........  .........  .......... .......... 
18. ... war ich 
traurig.......................................................................................  ..........  .........  .......... .......... 
19. ... hatte ich das Gefühl, daß die Leute mich nicht leiden 
können...............  ..........  .........  .......... .......... 
20. ... konnte ich mich zu nichts 
aufraffen.......................................................  ..........  .........  .......... .......... 
Bitte prüfen Sie, ob Sie alle Feststellungen beantwortet haben!  
ADS © 1993 Hogrefe  
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